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1.INTRODUCTION 
 
1.ORAL SOLID DOSAGE FORMS 
  A solid dosage form is drug delivery system that includes tablets, capsules, 
sachets and pills as well as a bulk or unit-dose powders and granules. Among the 
various dosage forms oral solid dosage forms have greater importance and occupy a 
prime role in the pharmaceutical market. Oral route of drug administration is widely 
acceptable and drugs administered orally as solid dosage form represents the preferred 
class of products. Over 90% of drugs formulated to produce systemic effects are 
produced as solid dosage forms. Because of these reason when ever New chemical 
entity (NCE) has discovered, which shows a sufficient pharmacological action, first 
the pharmaceutical company asks whether the drug is successfully administered by 
oral route or not. As a natural defence mechanism to prevent infection or dehydration 
many trees and shrubs are known to produce an aqueous thick exudation when the 
plants bark is injured. Eventually the solution dries up in contract with sunlight and 
air and a hard transparent brown-tint glass mass formed. This solid mass is known as 
Natural gum1. Excipients play an important role in dosage forms such as tablet, 
capsule, lotions, suspensions, syrups and ointments. Plant products serve as an 
alternative to synthetic products because of its local accessibility, environment 
friendly nature and low prices compared to imported synthetic products2. Plantago 
ovata mucilage has been evaluated in fast disintegrating tablet.Ocimum americanum 
Linn. Mucilage has been evaluated in disintegrating tablet3. Moringa gum is obtained 
from the tree Moringa Oleifera. Which is a water soluble gum extrudes from the bark 
on Moringa trees. In present study, an attempt was made to prove Moringa gum as 
disintegrant. The oral route of administration still continues to be the most preferred 
route due to its manifold advantages including: 
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 Tablets and capsules represent unit dosage forms in which the accurate dose of 
drug to show sufficient pharmacological action can be administered. In case of 
liquid oral dosage forms such as Syrups, Suspensions, Emulsions, Solutions and 
Elixirs the patient is asked to administer the medication of 5-30 ml. Such dosage 
measurements are typically error by factor ranging from 20-50 %, when the drug 
is self administered by patient. 
 Solid dosage forms are less expensive to shipping and less prone for the 
degradation when compared to liquid dosage forms4. 
1.1.TABLETS 
In 1843, the first patent for a hand operated device used to form a tablet was 
granted. Tablets are defined as solid preparations each containing a single dose of one 
or more active ingredients and obtained by compressing uniform volumes of particles. 
They are intended for oral administration, some are swallowed whole, some after 
being chewed. Some are dissolved or dispersed in water before being administered 
and some are retained in the mouth, where the active ingredient “liberated”. Tablets 
are used mainly for systemic drug delivery but also for local drug action. For systemic 
use drug must be released from tablet that is dissolved in the fluids of mouth, stomach 
and intestine and then absorbed into systemic circulation by which it reaches its site of 
action. Tablets remain popular as a dosage form because of the advantages, afforded 
both to the manufacturer [e.g. simplicity and economy of preparation, stability and 
convenience in packing, shipping and dispensing] and the patient [e.g. accuracy of 
dosage, compactness, portability, blandness of taste and ease of administration]. 
 
They may differ greatly in size and weight depending on the amount of drug 
substance present and the intended method of administration. They may have lines or 
break-marks and may bear a symbol or other markings. Tablets may be coated. 
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1.1.1. Advantages of Tablets 
The primary potential advantages of tablets are,  
 They are the unit dosage forms, which offer the great capabilities of all oral 
dosage forms for the greatest dose precision and the least content variability. 
 The cost is lower of all oral dosage forms. 
 They are the lightest and most compact of all. 
 They are in general the easiest and cheapest to packaging and shipment. 
 Product identification is potentially the simplest and cheapest, requiring no 
additional processing steps when employing an embossed or monogrammed 
punch face. 
 They may provide the greatest case of swallowing with the least tendency for 
hang up above the stomach, especially when coated, provided the tablet 
disintegration is not excessively rapid. 
 They lend themselves to certain special profile products, such as enteric or 
delayed release products. 
 They are better suited to large scale production than with other unit oral dosage 
forms. 
 They have the best combined properties of chemical, mechanical and 
microbiological stability of all the oral forms. 
 
1.1.2. Disadvantages 
In spite of all these advantages, tablet also possesses some disadvantages.  The 
disadvantages of tablets include the following 
 Some drugs resist compression in to dense compacts, owing to their 
amorphous nature or flocculent, low density character. 
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 Drugs with poor wetting properties, slow dissolution properties, intermediate 
to large dosages, optimum absorption high in the GIT or any combination of 
these features may be difficult or impossible to formulate and manufacture as 
a tablet that will still provide adequate or full drug bioavailability. 
 Bitter tasting drugs, drug with obnoxious odor or drugs that are sensitive to 
oxygen or atmospheric moisture may require encapsulation / entrapment prior 
to compression / coating4, 5, 6. 
 
1.1.3. PRINCIPLES OF DOSAGE FORM DESIGN 
 Drugs are rarely administered slowly as pure chemical substances, but are 
almost given as formulated preparations. The principle objective of dosage form 
design is to achieve a predictable therapeutic response to a drug included in the 
formulation. Before a drug substance can be successfully formulated in to a dosage 
form, many factors must be considered. These factors can be broadly grouped in to 
three categories. 
 Biopharmaceutical considerations (Factors affecting absorption of drugs) 
 Drug related factors (Physical and chemical properties of a drug) 
 Therapeutic considerations (Disease to be treated and patient factors) 
Among various orally administered dosage forms (tablets, capsules, syrup, 
solution etc), the tablet dosage form is the most widely used.7, 8 
Compressed tablets are defined as solid dosage forms made by compaction of the 
formulation containing the drug and certain fillers or excipients selected to aid in the 
processing and properties of the drug product. 
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1.2.1 CLASSIFICATION OF TABLETS 
I. Classification based on mode of administration. 
1) Chewable tablets 
2) Tablets to be swallowed 
3) Tablets used in oral cavity 
 Buccal tablets 
 Sublingual tablets 
 Troches and lozenges 
 Dental cones 
1)Tablets administered other than oral route 
 Implants 
 Vaginal tablets / suppositories 
II. Classification based on drug manufacturing process. 
1) Standard compressed tablets 
2) Multiple compressed tablets 
 Compression-coated tablets 
 Layered tablets 
1) Coated tablets 
2) Molded tablets (Tablet triturates) 
III. Classification based on drug release profile. 
1) Fast dissolving tablets 
2) Immediate release tablets 
3) Controlled Release tablets (Sustained Release Tablets) 
4) Delayed Release tablets (Enteric coated tablets) 
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IV. Tablets used to prepare solutions. 
 Effervescent tablets. 
 Dispersible tablets. 
 
1.2.2. CHEWABLE TABLET 
Chewable tablets which are required to be broken and chewed in between the 
teeth before ingestion. These tablets are given to the children who have difficulty in 
swallowing and to the adults who dislike swallowing.9 
 
  These tablets are intended to disintegrate smoothly in mouth at a moderate rate 
either with or without actual chewing, characteristically chewable tablets have a 
smooth texture upon disintegration, are pleasant tasting and leave no bitter or 
unpleasant taste. Successful tablet formulation development involves the careful 
selection of ingredients in order to manufacture a robust solid dosage form. Choosing 
the appropriate excipient to perform a specific function in a tablet formulation such as 
disintegration or lubrication can be critical to achieving acceptable manufacturing 
performance. Sweeteners, both naturally occurring and synthetic are one type of 
functional excipient commonly used in chewable tablet formulations to mask the 
unpleasant tastes and facilitate pediatric dosing. 10,11 Ideally upon chewing, they are 
broken down in the mouth and release their ingredients in the process and therefore, 
do not have much lag time as required for the disintegration of tablets before 
absorption from stomach. 12 Chewable tablets are often employed when the active 
ingredient is intended to act in a localized manner rather than systemically. 
 
 Chewable tablet is one that is palatable and may be chewed and ingested with 
little or no water. Manufacturing of chewable tablet is generally done using either wet 
granulation process or direct compression. Increasingly, micronized and submicron 
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forms of therapeutically and physiologically active substances are incorporated into 
tablet formulation to take advantage of the enhanced absorption characteristics of 
these forms. 13 They are also used in the administration of antacids and carminatives. 
Mannitol is widely used as an excipient in chewable tablet for its non-hygroscopic 
nature for moisture sensitive drugs. As we know difficulty in swallowing (Dysphasia) 
is common among all age groups, especially in elderly and in also seen of swallowing 
of conventional tablets and capsules. Geriatric and pediatric patients and travelling 
patients who may not have ready access to water are most need of easy swallowing 
dosage forms like chewable tablets. The composition of chewable tablet consists of 
gum core, which may or may not be coated. The core is composed of an insoluble 
gum base like fillers, waxes, antioxidants, sweeteners, flavouring agents. The 
percentage of gum base varies from 30-60% depending upon the base used and its 
properties. A flavouring agent is included to make it more palatable. 
 
 1.2.3 Advantages of chewable tablets14, 15 
Chewable tablets are generally chewed in the mouth prior to swallowing and 
are not expected to swallow intact. The main purpose of a chewable tablet is to 
provide proper unit dosage forms of medication which can easily to administer to 
children or to the elderly who have difficulty in swallowing a tablet intact. The 
chewable tablet has some specific advantages. 
 Better bioavailability through by passing disintegration (increase dissolution). 
 Improved patient acceptance (especially pediatric) through pleasant taste patient 
convenience, need no water for swallowing. 
 Possible to use as a suitable for liquid dosage forms where rapid onset of action 
is needed adsorption of the drug is faster product distinctiveness through 
marketing perspective. 
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 The large size of the dosage forms is difficult to swallow. 
 In such case, chewable tablets offer effectiveness of therapeutic agent is 
improved by the reduction in size that occurs during mastication of tablets 
before swallowing. 
 
1.2.4 Disadvantages of chewable tablets 
There are of course some limitations to the use of chewable having bad tasting 
drug and extremely high dose level. 
 It contains sorbitol which causes diarrhea and flatulence flavoring agents present 
in a chewable tablet may cause an ulcer in the oral cavity. 
 Prolonged chewing of chewable tablets results in pain in facial muscles. 
 They are hygroscopic in nature, so must keep in a dry place they slow the 
fragile, effervescence granules property. Since they tablets having insufficient 
mechanical strength. So careful handling is required. 
 
1.2.5. METHOD OF MANUFACTURING 16, 17, 18 
The chewable tablets were prepared by using the following method. 
1. Non-aqueous granulation/dry granulation. 
2. Aqueous granulation/wet granulation 
3. Direct compression. 
 
 Granulation 
Granulation is the process in which primary powder particles are made to adhere 
to form larger, multi-particles entities Called granules. Pharmaceutically granules 
have a size range between 0.2 to 4.0 mm .granulation is used to improve flow and 
compressibility of the powders and segregation of the blend compounds. Granulation 
is mainly done by using two techniques. 
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1. Dry granulation 
  It is a novel method for semi-automatic production of granules. the method is 
applicable to any solid dosage for pharmaceuticals products.dry granules method 
replace existing solid dosage form development and manufacturing technology 
offering more rapid. in the process, the powder mixture is compressed without the use 
of heat and solvent. two methods are used for dry granulation. The more widely used 
slugging where the powder is recompressed and resulting tablet is milled to yield the 
granules. 
2. Wet granulation 
  Wet granulation is the most commonly used granulation method. This process 
involves wet massing powder blend with a granulating liquid, wet sizing, and drying. 
It can be removed from the volatile materials. That it can be removed drying and most 
be Non-toxic in nature. The typical liquid includes water, ethanol and isopropyl 
alcohol. in this traditional wet granulation method, the wet mass is forced through the 
sieve to produce wet granules which are subsequently dried. 
3. Direct compression 
  Direct compression is the most popular choice because it provides the shortest. 
Most effective and least complex to produce tablets. This method has mainly used a 
group of ingredients can be blended. This is more suitable for moisture and heat 
sensitive API’s since it eliminates wetting and drying steps and increases the stability 
of active ingredient by reducing to detrimental (Harmful) effects. In the process of 
API mixed with the excipients and lubricants, followed by compression.  
 
 
 
1.2.6. Mechanism of action of chewable tablets19, 20 
Chemoreceptor’s on the tongue 
Taste is brain interpretation of chemicals triggers on the tongue. This is on 
taste buds. Molecules interact with taste receptors on the tongue to taste sensation 
.This sensation is the result of signal transudation from the receptor organs for taste, 
commonly known as taste buds. These taste buds contain very sensitive nerve 
endings, when there dissolve in the saliva. Which produce and transmit an electrical 
impulse to the seventh, ninth, tenth to the area of the brain. 
 
Figure no.1. Taste buds in cell Structure 
 
1.2.7. PHYSIOLOGY OF TASTE 
The sense of taste is mediated by taste bud, which is a group of taste receptor 
cell (50-100 cells), bundled in a cluster like bannans and gives a sensation of taste via 
sensory neurons to central nervous system (CNS) in the brainstem. Taste buds are 
chemoreceptor stimulated by chemicals dissolved in saliva from oral ingested 
medicaments and enter via the taste pore followed by interaction with surface proteins 
known as taste receptors causing electrical change within taste cells, which cause the 
transmission of signals to the brain. 
Four fundamental sensations of the taste have been described. 
1. Sweet. (Sugar, glycerol) 
2. Salty. (Sodium) 
3. Bitter. (Quinine, nicotine) 
4. Sour. (Acidic substance) 
 
1. SALTY TASTE (EDGE, UPPER PORTION) 
Salty taste is one of the four receptors of the tongue; they are located on the 
edge and upper front portion of the tongue. 
2. SWEET TASTE (TIP) 
The sweet taste is one among the four taste receptors in the tongue. There are 
found on tip of the tongue.  
3. SOUR TASTE (ALONG SIDES IN BACK) 
The sour taste is also one of the four taste receptors of the tongue. They occur 
at sides of the tongue and are stimulated mainly by acids. 
4. BITTER TASTE (BACK) 21 
The bitter taste is the last and one of the four taste receptors on the tongue. 
That is located towards the back of the tongue. It is stimulated by a variety of 
chemicals substances, most of which are organic compounds, although some 
inorganic compounds such as magnesium and calcium also produce bitter sensations. 
 
Figure no.2. Taste buds 
1.3. TASTE SIGNALS PATHWAYS 22 
Taste transduction begins with the interaction on the taste. (eg. medicine, 
food) with taste receptors cells in taste buds. The tastant binds with g-protein coupled 
receptors (GPCRS) cells triggering the release of the G-protein called gustducin.the 
process of taste  sensation begins when gustducin activates the effector enzymes 
phosphodiesterase IA (PDE) or phospholipase C BETA-2(PLC).the effectors enzymes 
then change the intracellular level second messengers such as cyclic adenosine 
monophosphate (CAMP),Inositol, 1,4 ,5 –triphosphate(IP3) and diacylglycerol 
(DAG).the second messengers Activate ion channel including calcium channel on the 
extra cellular membrane. This ionization depolarizes the cell causing the release of 
neurotransmitters that send a nerve impulse to the brain that carries the signal of bitter 
taste and taste blockers work by interfering with taste transduction.  
 
Figure no.3. Taste signal pathways 
 
1.3.1. TASTE BLOCKING MECHANISM 23 
Taste sensation begins with gustducin activates the effectors enzyme 
phosphodiesterase IA (PDE)phospholipase C beta-2(PLC).the effectors enzyme then 
change the intracellular level of second messengers such as cyclic adenosine 
monophosphate (cAMP)1,4,5-triphosphate (IP3)and diacylglycerol(DAG).the second 
messengers active calcium ion channel inside the  cell neurotransmitters to the nerves. 
Impulse transmits into the brain bitter taste and taste blockers work by interfering 
with taste transduction. 
 
Figure no.4. Taste blocking mechanism 
1.3.2. TASTE MASKING TECHNOLOGY 
Taste masking is defined as perceived reduction of an undesirable taste that 
would otherwise exist. 24Methods commonly used for the two types. 
1. The chemical method that prevents from the interaction of taste buds with drugs. 
2. Physical method. 
 
1.3.3. TWO APPROACHES BASED ON THE BAD TASTE OF THE DRUG 
          1. By reducing the solubility of drug in the PH of the saliva (5.6-6.8) 
          2. By altering the affinity and nature of drug will interact with receptors.25 
 
1.3.4. AN IDEAL TASTE MASKING PROCESS AND FORMULATION 
SHOULD HAVE THE FOLLOWING PROPERTIES 
1. Involve the least number of equipment and process. 
2. Effectively mask the taste with as few Excipients .which are economically and    
easily available.    
3. No adverse effect on the drug bioavailability. 
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4. Least manufacturing cost. 
5. Can be carried out room temperature. 
6. Require excipients that have a high margin of safety. 
7. Rapid and easy to prepare.    
 
1.3.5. FACTORSCONSIDERATION DURING THE TASTE MASKING 
FORMULATION PROCESS INCLUDES 
           1. The extent of the bitter taste of the API. 
           2. Required dose load. 
           3. Drug particulate shape and size distribution. 
           4. Drug solubility and ionic characteristics. 
           5. Required disintegration and dissolution rate of the finished product. 
           6. desired bioavailability. 
           7. Desired release profile. 
           8. Required dosage forms. 
 
1.3.6. TASTE MASKING TECHNOLOGIES26 
          To achieve the goal of taste abatement of the bitter or unpleasant taste of the 
drug. The various methods involved. 
1. Taste masking with flavors, sweeteners& amino acids. 
2. Taste masking by granulation. 
3. Taste masking by Microencapsulation.  
4. Ion Exchange Resins. 
5. Taste masking by formulation of inclusion complexes. 
6. Taste masking by Prodrug approach. 
7. Solid dispersion system. 
15 
 
8. PH Modifiers. 
9. Taste masking by adsorption. 
10. Taste masking by relation. 
11. Multiple Emulsions. 
12. Development of Liposome. 
13. Miscellaneous taste masking approaches 
• By effervescent agents  
• Rheological modification  
• Continuous multipurpose melt (CMT) Technology 
 
1.Tastemaskingwithflavours,sweetners,andaminoacids 
 This technique is simplest approach taste masking. But this technique was not 
very successful for highly bitter taste drugs taste masking failure. Artificial 
sweeteners and flavors are generally being used alone with other taste masking 
techniques to improve the efficiency of taste. 
 
A.)Flavors 
    1.) Complementary to existing of the flavor of the drug. 
    2.) The known popularity of particular flavors.  
    3.) Allergy 
    4.) Age of patients.  
 Natural vs. synthetic: 
 Cheaper. 
 More readily available. 
 Less variable in chemical composition. 
 More stable flavoring agents for taste masking. 
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Natural flavors : Raspberry juices; Liquorices. 
Extract  :  lemon orange spirits 
Syrup   :  ginger tinctures: anise cinnamon aromatic. 
Water   :  peppermint lemon aromatic oils. 
Synthetic flavors  : alcoholic solution: aqueous solutions: powders 
 
B.)Sweeteners 
            1. Complement flavors associated with sweetness 
            2. Soothing flavors associated with the throat. 
 
Natural sweetener - sucrose, glucose, fructose, mannitol. 
Artificial sweeteners - saccharin, saccharin sodium, aspartame. 
Nutritive sweeteners - sucrose, fructose, glucose. 
Non-nutritive sweeteners- Aspartame, sucralose, Neotame, Saccharine.  
Polyols - mannitol, sorbitol, xylitol, maltitol. 
 Novel sweeteners - Trehalose, tagatose. 
C. Amino acids 
 Amino acids and they're (alanine, taurine, glutamic acid, glycine) in 
combination with bitter drugs reduce the drug. Ampicillin improved markedly by 
preparing its granules with them with an additional quantity of glycine, sweeteners, 
flavors and finally compressing them into tablets. 
 
 2. Taste masking by granulation 
 Granulation is a less expensive, rapid operation and an easily scalable taste 
masking technology. This step can be exploited as a mean for taste masking of 
slightly bitter tasting drug. Granulation lowers the effective surface area of the bitter 
substance that come in contact with the tongue upon oral intake. Liquid and low 
17 
 
melting point waxes such as glycerol palmitostearate, glyceryl behenate and 
hydrogenated castor oil are commonly used ingredients during the granulation to 
achieve taste masking. 
 
3. Taste masking by microencapsulation 
Microencapsulation is a process by which very tiny droplets or particles of 
liquid or solid material are surrounded or coated with a film or polymeric material. 
Coating is an extremely useful technique for a number of applications in 
pharmaceutical field. Although it is used primarily for production of sustained release, 
Gastro-intestinal dosage forms, it also has major applications in masking the 
unpleasant taste. It is important to understand that only soluble portion of the drug can 
generate the sensation of taste. Coating the active drug with a properly selected 
polymer film can reduce its solubility in saliva and thus taste could be masked. 
Coating the drug particles created a physical barrier between the drug and the taste 
buds and taste of active could be masked. The goal of Microencapsulation may be 
accomplished by any of the following techniques. 
• Air suspension coating 
• Spray drying and spray congealing 
• Coacervation - phase separation 
• Solvent evaporation 
• Multiorifice - centrifugal process 
• Pan coating 
• Interfacial polymerization 
Polymers used for coating in microencapsulation 
 Coating is an extremely useful technique for number of applications in the 
pharmaceutical field. It is classified based buds. Cyclodextrin is most widely used 
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complexing agent for inclusion type complexes. It is sweet, non toxic, cyclic 
oligosaccharide obtained from starch. The following are the examples of drugs that 
the bitter taste can be suppressed by making inclusion complexes. 
 
4. Ion exchange resins 
 Ion exchange resins (IER) have received considerable attention from 
pharmaceutical scientists because of their versatile properties as drug delivery 
vehicles. In past few years, IER have been extensively studied in the development of 
Novel drug delivery system and other biomedical applications. Several ion exchange 
resin products for oral and peroral administration have been developed for immediate 
release and sustained release purposes. Bitter tasting drugs can be absorbed onto ion 
exchange resins, thus effectively removing them from solution during the transit 
through the mouth, at salivary pH 6.8, remains in intact form making the drug 
unavailable for the taste sensation. Various studies have revealed that ion exchange 
resins are equally suitable for drug delivery technology. Some ion exchange resins 
used widely for taste masking purpose in industries are Amberlite IRP64, Amberlite 
IRP69, Indion 204, Indion 214, Kyron T-114 and Kyron T-104. 
 
5. Taste masking by formulation of inclusion complexes 
 Inclusion complexation is a process in which the guest molecule is included in 
the cavity of a host or complexing agent. The complexing agent is capable of masking 
bitter taste of drug by either decreasing its oral solubility on ingestion or decreasing 
the amount of drug particles exposed to taste. 
 
6. Taste masking by prodrug approach 
 Chemical modification, including prodrug design is an effective method for 
reducing solubility, and thereby improving taste. A prod rug is chemically modified 
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inert drug precursor which upon biotransformation liberates the pharmaceutically 
active parent compound. Bitterness of a molecule may be due to the efficiency of the 
taste receptor substrate adsorption reaction, which is related to the molecular 
geometry of the substrate. If alteration of the parent molecule occurs by derivative 
formation, the geometry is altered, affecting the adsorption constant. Thus the 
magnitude of a bitter taste response or taste receptor-substrate adsorption constant 
may be modified by changing the molecular configuration of the parent molecule. The 
extremely bitter antibiotics have been the focus of much work in reversible drug 
modification. Taste masking of drug.’ 
 
7. Solid dispersion system 
 Solid dispersion has been defined as dispersion of one or more active 
ingredients in an inert carrier or matrix at solid state prepared by melting (fusion) 
solvent or melting solvent method. Recently solid dispersions were introduced as a 
taste masking technology. Tsau and Damani (1994) disclosed a drug-polymer matrix 
composition to achieve the taste masking of dimenhydrinate. Amine or amide group 
of dimenhydrinate can have a physical and chemical interaction with the carboxylic 
acid and esters groups of copolymers such as shellac, zein and cellulose acetate 
phthalate hydrophobic polymers and long chain fatty acids have been used to achieve 
the taste masking by solid dispersion. This approach usually requires a higher 
concentration of excipients compared to other taste masking techniques. Natural 
polymers such as shellac and zein, and enteric polymers like derivatives of acrylic 
acid polymers and phthalate are good choices to develop the taste masked solid 
dispersions. 
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8. Ph modifiers 
 Many natural and synthetic polymers, resins and waxes alone or in 
combinations have been employed for taste masking. The enteric polymers like 
eudragit L are used for taste masking but the pH of saliva is near 5.8 and these 
polymers solubilize at pH beyond 5.5 so there is a possibility of drug being partially 
leached. Therefore there is a need for the development of taste masking polymer such 
that the bitter taste is completely masked by the polymer at the pH of saliva in mouth 
and in the reconstitution medium as in case of the liquid orals and further which is 
able to protect the drug in a biologically active form, from the moisture in the dosage 
form and releasing the drug rapidly in the stomach without affecting its absorption 
and bioavailability. Developed to supply these drugs to the oral cavity for buccal, 
sublingual, and gingival absorption. The formulation contains the drug in combination 
with effervescent agent to promote their absorption in the oral cavity and to mask 
their bitter taste. An additional pH adjusting substance was also included in fentanyl 
formulation for further promotion for absorption.  
 
9. Taste masking by adsorption 
 Adsorbates are commonly used in taste masking technologies. Adsorbate of 
bitter tasting drug can be considered as the less saliva soluble versions of these drugs. 
Adsorption involves preparing a solution of the drug and mixing it with an insoluble 
powder that will absorb the drug, removing the solvent, drying the resultant powder, 
and then using these dried adsorbates in the preparation of the final dosage form. 
Many substrates like veegum, bentonite, silica gel and silicates can be used for the 
reparation of Adsorbate of bitter drugs. The bitter taste of ranitidine is masked by 
forming an adsorbate with a synthetic cation exchange resin. 
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10. Taste masking by gelation 
 Water insoluble gelation on the surface of tablet containing bitter drug can be 
used for taste masking. Sodium alginate has the ability to cause water insoluble 
gelation in presence of bivalent metal ions. Tablet of amiprolose hydrochloride have 
been taste masked by applying a undercoat of sodium alginate and overcoat of 
calcium gluconate. In presence of saliva, sodium alginate reacts with bivalent calcium 
and form water insoluble gel and thus taste masking achieved. 
11. Multiple emulsions 
 A novel technique for taste masking of drugs employing multiple emulsions 
has been prepared by dissolving drug in the inner aqueous phase of w/o/w emulsion 
under conditions of good shelf stability. The formulation is designed to release the 
drug through the oil phase in the presence of gastrointestinal fluid. 
12. Development of liposome 
  Another way of masking the unpleasant taste of therapeutic agent is to entrap 
them into liposome. For example, incorporating into a liposomal formulation prepared 
with egg phosphatidyl choline masked the bitter taste of chloroquine phosphate in 
HEPES (N-2-hydroxyetylpiperzine-N’- 2- ethane sulfonic acid) buffer at pH 7.2. 
13. Miscellaneous taste masking approaches 
• By effervescent agents 
Effervescent agents have been shown to be useful and advantageous for oral 
administration of drugs and have been employed for use as taste masking agents for 
dosage forms that are not dissolved in water prior to administration. A chewing gum 
composition of bitter medicament was formulated to supply the medicament to oral 
cavity for local application or for buccal absorption. It comprise a chewing base, an 
orally administrable medicament, a taste masking generator of carbon dioxide, and 
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optionally a taste bud desensitizing composition (e.g., oral anesthetic such as 
benzocaine) and other non active material such as sweeteners, flavoring components, 
and fillers. Recently, effervescent tablets of fentanyl and prochlorperazine were 
located and dissected from the surrounding tissue and cut proximally. An 
ac‐amplifier and an electronic integrator are used to respectively amplify and 
integrate the nerve impulses. The peak height of the integrated response is then taken 
as the magnitude of response. 
 
• Rheological modification 
Increasing the viscosity with rheological modifier such as gums or 
carbohydrates can lower the diffusion of bitter substances from the saliva to the taste 
buds. Acetaminophen suspension can be formulated with xanthan gum (0.1‐0.2%) and 
microcrystalline cellulose (0.6‐1%) to reduce bitter taste. The antidepressant drug 
mirtazapine is formulated as an aqueous suspension using methonine (stabilizer) and 
maltitol (thickening agent). Maltitol is stable in the acidic pH range of 2 to 3 and 
besides masking the unpleasant taste of the drug, it also inhibit its undesirable local 
anesthetic effect . 
• Continuous  multipurpose  melt (cmt)technology 
The CMT method was developed for the continuous granulation and coating of 
pharmacologically active substances. It was concluded that this method could be 
successfully applied for taste masking of bitter drug. 
1.3.7 Criteria for selection of chewable tablets 
Chewable tablets must be chewed before swallowing and typically contain a 
combination of colors, flavors, and sweeteners. This tablet form is suitable for 
ingredients with neutral or sweet flavor or tablets that contain a large amount contain a 
lot of active ingredients that do not lend themselves to being swallowed whole. 
 
 
 
 
 
CHAPTER II 
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2. LITERATURE REVIEW 
S.V.Sai kumar et al., (2010) The aim of this work was to develop and validate 
simple, accurate and precise spectroscopic methods (multicomponent, dual 
wavelength and simultaneous equations) for the simultaneous estimation and 
dissolution testing of ofloxacin and ornidazole tablet dosage forms. The medium of 
dissolution used was 900 ml of 0.01N HCl, using a paddle apparatus at a stirring rate 
of 50 rpm. The drug release was evaluated by developed and validated spectroscopic 
methods. Ofloxacin and ornidazole showed 293.4 and 319.6nm as λmax in 0.01N HCl. 
The methods were validated to meet requirements for a global regulatory filing. The 
validation included linearity, precision and accuracy. In addition, recovery studies and 
dissolution studies of three different tablets were compared and the results obtained 
show no significant difference among products44. 
 
B.Sree giri Prasad et al., (2013) The objective of the present study is to develop 
chewable tablets containing different pharmaceutical compositions with simple 
manufacturing procedures using different excipients. Mannitols, L-HPC 11, 
Aspartame, Crospovidone, Crospovidone, Aerosil, and Magnesium Stearate are used 
as excipients for effective formulation of anti-asthmatic drug Montelukast. 
Montelukast chewable tablets were prepared by both wet granulation and Direct 
Compression methods using suitable excipients. The chewable tablets were better 
presented using artificial sweetener Aspartame as flavouring agent. A total of eight 
formulations were prepared and the granules were evaluated for pre-compression 
parameters. The formulated tablets were evaluated for post-compression parameters. 
The results showed that all the physical parameters were within the acceptable limits. 
I.R spectral studies revealed that there was no interaction between the drug and 
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excipients. The in vitro release study of formulation F7 showed 98.85%drug release at 
the end of 30 min. The stability studies for the formulation F7 showed no significant 
changes and the study concludes that formulation F7 showed better characteristics of 
chewable tablet45. 
 
Bhupendra kumar poudel et al., (2014) The objective of the present study is to 
develop chewable tablets containing different pharmaceutical compositions with 
simple manufacturing procedures using different excipients. Mannitols, L-HPC 11, 
Aspartame, Crospovidone, Crospovidone, Aerosil, and Magnesium Stearate are used 
as excipients for effective formulation of anti-asthmatic drug Montelukast. 
Montelukast is a selective, orally acting leukotriene receptor antagonist that is used 
for the treatment of asthma and seasonal allergic rhinitis. Montelukast chewable 
tablets were prepared by Direct Compression methods using suitable excipients. The 
chewable tablets were better presented using artificial sweetener Aspartame as 
flavouring agent. A total of forteen formulations were prepared and the granules were 
evaluated for pre-compression parameters. The formulated tablets were evaluated for 
post-compression parameters .The results showed that all the physical parameters 
were within the acceptable limits. The in vitro release study of all the formulations 
showed good release. The study concludes that aforementioned excipients can be used 
to design chewable montelukast sodium tablets46. 
 
V.Anusha et al., (2012) Albendazole chewable tablets were prepared by wet 
granulation method. Using two superdisintegrants such as croscarmellose sodium and 
sodium starch glycolate. A total of eight formulations were prepared and the granules 
were evaluated for precompression parameters such as angle of repose, bulk density, 
tapped density, compressibility index and Hausner’s ratio. The formulated tablets 
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were evaluated for diameter, thickness, hardness, weight variation, friability, 
disintegration and drug content. The results showed that all the physical parameters 
were within the acceptable limits. IR spectral studies revealed that there was no 
interaction between the drug and excipients. The in vitro release study of formulation 
F8 showed81.03%drug release at the end of 30 min. The stability studies for the 
formulation F8 showed no significant change in disintegration time, drug content and 
percentage drug release after stored at 40o±2oC/75±5%RH for a period of30 days. 
Hence the study concludes that formulation F8 showed better characteristics of 
chewable tablet47. 
 
Bharat Parashar et al., (2012) Albendazole is a benzimidazole derivative with broad 
spectrum anthelmenthic activity and excellent tolerability. Orally it is rapidly 
absorbed and metabolized to sulfoxide and sulfone, which may be responsible for its 
anthelmenthic action. Single dose administration of albendazole has produced cure 
rates in ascarisis, hookworm and enterobiasis which are comparable to three day 
treatment with mebendazole. Albendazole chewable tablets (400 mg) were prepared 
by three methods viz. non aqueous granulation, aqueous granulation and direct 
compression and were named as NAG, AG and DC respectively. Tablet prepared by 
these three methods were evaluated by different parameters such as average weight, 
hardness, Carr’s index, tapped density, friability, disintegration, content uniformity 
test, in vitro dissolution etc. All the parameters were found within the specifications. 
The study on the dissolution profile revealed that product ‘DC’ had faster dissolution 
rate while compared to remaining batches and marketed product. Assay values were 
within the limits of 90% to 110%48. 
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V.Gopal et al., (2012) various formulations of Loratadine Chewable tablets 
containing different pharmaceutical compositions with simple manufacturing 
procedures were developed by using different excipients. The excipients used here are 
Lactose, Mannitol, Ethyl cellulose, microcrystalline cellulose, Maize Starch, Citric 
Acid, Aspartame, Colloidal silicon dioxide, Magnesium Stearate, D & C Yellow No 
10 and Raspberry flavour. Oral chewable tablets are the most preferred among the 
conventional dosage forms due to its aesthetic appeal and ease of administering to 
children, which has entered the market. The chewable tablet was better presented 
using artificial sweetener Aspartame and Raspberry flavour as flavouring agent. The 
tablets were evaluated for weight variation, hardness, friability; drug content and 
mouth feel along with in-vitro dissolution. As per monograph, the chewable tablets 
are not required to comply with disintegration test. Wet granulation process using 
Mannitol, Lactose, Micro crystalline cellulose (Avicel-CE 15), Ethyl cellulose and 
Sweeteners and Flavours were found to be simple and robust method to prepare 
chewable tablets49. 
 
M.Rajesh et al., (2012) Albendazole chewable tablets were prepared by wet 
granulation method. Using two superdisintegrants such as croscarmellose sodium and 
sodium starch glycolate. A total of eight formulations were prepared and the granules 
were evaluated for precompression parameters such as angle of repose, bulk density, 
tapped density, compressibility index and Hausner’s ratio. The formulated tablets 
were evaluated for diameter, thickness, hardness, weight variation, friability, 
disintegration and drug content. The results showed that all the physical parameters 
were within the acceptable limits. IR spectral studies revealed that there was no 
interaction between the drug and excipients. The in vitro release study of formulation 
F8 showed81.03%drug release at the end of 30 min. The stability studies for the 
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formulation F8 showed no significant change in disintegration time, drug content and 
percentage drug release after stored at 40o±2oC/75±5%RH for a period of30 days. 
Hence the study concludes that formulation F8 showed better characteristics of 
chewable tablet50. 
 
Mohit kumar et al., (2014) Formulation of chewable tablet of amoxicillin potassium 
clavulanate and perform the in vitro bioequivalence study with trying to enhance the 
bioavailability of innovator formulation. chewable tablet are given to the adults who 
dislike swallowing and to children who difficulty in swallowing and total 10 
formulation were made with different concentration of microcrystalline cellulose & 
crosscarmellose sodium .the formulation were evaluated for weight 
variation,hardness,friability data indicates good mechanical resistance of the tablet. 
All tablet disintegrate in between 3-5 min.the optimized the formulation showed good 
disintegration time and release profile maximum drug being release marketed 
preparation at all time intervals51. 
 
Y. Kranthi Kumar et al., (2014)  In this research study the effect drug release of 
albendazole chewable tablets has been determined. The drug release is calculated by 
using disintegration process which is directly related to with the hardness of tablets. 
The tablets are prepared by using three types of granulating methods are non-aqueous 
granulation, aqueous granulation and direct compression. The tablets are evaluated by 
calculating different parameters such as hardness, friability, disintegration, assay and 
in vitro dissolution studies. The % drug release was determined by using U V 
spectrophotometry. In the three techniques and the non-aqueous granulation was the 
better technique for the formulation of tablets, dissolution rate and % drug release 
other than aqueous granulation and direct compression method. So by this we can say 
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the non- aqueous technique is gives immediate drug release by which the drug can be 
used at the time of emergency and gives relief to the patient and the chewable tablets 
can used for the children easily. The present study was to prepare the chewable 
albendazole tablets by granulating techniques i.e. non aqueous granulation, aqueous 
granulation and direct compression methods and to compare the drug release profiles 
of the tablets with the marketed52.  
 
Swati Jagdale et al., (2010) Levamisole is a synthetic imidazothiazole derivative that 
has been widely used in treatment of worm infestations in both humans and animals. 
As an anthelmintic, it probably works by targeting the nematode nicotinergic acetyl-
choline receptor. In the market, levamisole tablets are available in the form of tablets. 
Geriatric and paediatric patients find it difficult to swallow these tablets. So in order 
to avoid this problem, chewable tablets are most pre-ferable. The chewable tablets of 
levamisole were prepared by using lactose or mannitol along with sodium starch 
glycolate in concentration ratios especially for paediatric use. Sodium saccharin and 
vanilla were used as sweeten-ing agent and flavouring agent respectively. From the 
disintegration studies, it was observed that the formulation containing 1.6% w/w of 
sodium starch glycolate shows minimum disintegration time whereas formulation 
having no or less concentration of sodium starch glycolate shows increase in 
disintegration time. It was observed that the formulation containing lactose shows less 
disintegration time than formulation containing mannitol53. 
 
Huda.i.G et al., (2013) In the present work, chewable dispersible tablets of 
Pregabalin were designed by preparing taste masked granulates of Pregabalin with 
Eudragit EPO.  The tastes masked granulate was prepared by granulation technique in 
Rapid Mixer Granulator using Eudragit EPO with a drug: Eudragit EPO ratios 1:0.15, 
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1:0.2, 1:0.25 and 1:0.3 (% w/w). Assay content and In-vitro decomplexation studies 
confirmed taste masking of granulate. It was found that maximum taste masking of 
drug with Eudragit EPO was noted at a ratio of 1:0.25. Drug release from Drug: 
Eudragit EPO complex in salivary pH imparts slight after bitter taste which was 
overcome by addition of sucralose during granulation. A study on different flavor is 
studied to enhance mouth feel. The prepared batches of tablets were evaluated for 
hardness, friability, drug content uniformity and in vitro dispersion time. Based on 
acceptable physical characteristic, formulations were tested for in vitro drug release 
pattern (in 0.06M Hydrochloride) 54. 
 
O.G .Bhusnure et al., (2015) Chewable tablets which are required to be broken and 
chewed in between the teeth before ingestion. These tablets are given to the children 
who have difficulty in swallowing and to the adults who dislike swallowing. These 
tablets are intended to disintegrate smoothly in the mouth at a moderate rate either 
with or without actual chewing, characteristically chewable tablets have a smooth 
texture upon disintegration, are pleasant tasting and leave no bitter or unpleasant taste. 
Many active pharmaceutical ingredients (API) inherently possess a bitter taste. Nearly 
20% of American adults surveyed complained of bad aftertastes or struggling to 
swallow when trying to take medication.  The most popular oral dosage forms include 
liquids, powders, granules, orally disintegrating tablets (ODT), and chewable tablets. 
For solid oral dosage forms like orally disintegrating tablets and chewable tablets, 
break-lines can be included in the tablet design to adjust dosing. As a result, chewable 
tablets has seen an increased interest from the pharmaceutical industry in taste-
masking technologies55 
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K.Khar et al., (2004) Taste is one of the most important parameters governing patient 
compliance. Undesirable taste is one of several important formulation problems that 
are encountered with certain drugs. Oral administration of bitter drugs with an 
acceptable degree of palatability is a key issue for health care providers, especially for 
pediatric patients. Several oral pharmaceuticals, numerous food and beverage 
products, and bulking agents have unpleasant, bitter‐tasting components. So, any 
pharmaceutical formulation with a pleasing taste would definitely be preferred over a 
competitor's product and would translate into better compliance and therapeutic value 
for the patient and more business and profits for the company. The desire of improved 
palatability in these products has prompted the development of numerous 
formulations with improved performance and acceptability. This article reviews the 
earlier applications and methodologies of taste masking and discusses the most recent 
developments and approaches of bitterness reduction and inhibition for oral 
pharmaceuticals56. 
 
Vishnumurthy vummaneni et al., (2012) Taste, smell and texture are the important 
factors in development of oral dosage forms. Taste is now a factor influencing the 
patient compliance and product quality. “The worser the taste of the medication, the 
better the cure” an older attitude which now totally changed. Taste masking of 
obnoxious drugs has gained the importance as the most of them are administered 
orally. This reason is an initiative for the development of various taste masking 
technologies by which the characteristics of the dosage form is improved and good 
patient compliance is achieved. The main objective of this review is to explore 
various methodologies for masking the taste of obnoxious drugs, applications, 
evaluation and also the recent trends in taste masking technologies57.  
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Basim Deshmukh et al., (2014) Sildenafil citrate is a pharmacological agent which 
has proven useful in treatment of erectile dysfunction, pulmonary arterial 
hypertension as well as high altitude motion sickness. Sildenafil citrate exhibits an 
absolute bioavaibality of about 40% and is reported to result in maximum observed 
plasma concentration of about 30-120 minutes following after oral administration. 
Sildenafil citrate exhibits low water solubility,namely 3.5mg/ml. This low water 
solubility with its high presystemic metabolism have contributed to its low oral 
bioavailability. Thus,there is a need to to improve the bioavailability of sildenafil 
citrate. Fast dissolving tablet of sildenafil citrate were prepared with a intention to 
gain pre gastric absorption that will eliminate the presystemic metabolism of drug. 
Attempts were also made to improve the acqueous solubility of the drug by forming 
its nanocrystals. The nanocrystals of sildenafil citrate were formed by 
nanoprecipitation technique and were evaluated for particle size and shape by 
scanning electron microscopy and were also subjected to DSC and FTIR analysis.This 
formed nanocrystals were further considered as API for the fast dissolving tablet. The 
formulated F3 formulation(fast dissolving tablet containing cross povidone as 
polymer and sildenafil citrate nanocrystals) shows rapid drug release within 2 minutes 
as compared to the tablet containing pure drug58. 
 
 Aditi Tripathi et al., (2011) Taste is an important parameter in case of drugs 
administering orally. Taste masking becomes a prerequisite for bitter drugs to 
improve the patient compliance especially in the pediatric and geriatric population. 
The problem of bitter taste of drug in pediatric formulations is a challenge to the 
formulators in the present scenario. Masking the bitter taste of drugs is a potential tool 
for the improvement of patient compliance which intern decides the commercial 
success of the product. Two approaches are commonly utilized to overcome the bad 
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taste of the drug. The first includes reduction of drug solubility in the saliva and 
second approach is to alter the ability of the drug to interact with taste receptor. 
Various methods are available to mask the undesirable taste of the drugs. Some of 
them are coating of drug particles, by formation of inclusion complexes, molecular 
complexes of drugs with other chemicals, solid dispersions, melting method, micro 
encapsulation, prodrugs, mass extrusion methods and ion exchange resins59. 
 
 Rushiraj Jani et al., (2016) Sildenafil citrate is one of the most effective agents for 
treatment of erectile dysfunction which acts by inhibiting thecGMP-specific 
phosphodiesterase type 5. Extensive research work is focused on flash release dosage 
forms and especially fast dissolving films are successful to attract pharma-industry 
due to ease of preparation and opportunityto extend patent life. Films are widely 
acceptable in patients too because of quick onset and user friendliness. Theaim of 
present study was to prepare fast dissolving films of sildenafil citrate which provides 
product differentiation from other marketed products and also quick disintegration of 
highly bitter drug with satisfactory taste masking inoral cavity. Film formulation can 
be taken within the pocket and patient can take it without need of water by 
simplyputting it on tongue without any grittiness that is frequently found during 
disintegration of orodispersible tablets.the formulation  will disintegrate within minute 
and ultimately provides good bioavailability and quickonset. The IR studiesconfirmed 
complete complexation of drug with taste masking resin. Using experimental design, 
the preparedformulations were evaluated for in vitro dissolution, solution time and 
their physicomechanical parameters mainlytensile strength.60  
 
Hiren Patel et al., (2012)  The present study was undertaken to formulate and 
evaluate transdermal gel of Sildenafil citrate. Sildenafil citrate is a drug of choice used 
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in the treatment of premature ejaculation disorder. Transdermal gel has gained more 
and more importance because the gel based formulations are better percutaneously 
absorbed than creams and ointment bases. Therefore, transdermal gel of Sildenafil 
citrate was prepared using different polymers such as carbopol 934P containing 
permeation enhancer PEG 400 at different proportions. The study encompasses 
compatibility studies using FTIR spectra, drug content, viscosity, spreadability, and 
pH determination. Further the optimized formulation evaluated by in vitro and ex vivo 
diffusion study. Optimized formulation subjected to stability as well as ex vivo study. 
The preliminary compatibility studies conducted revealed that there was no 
interaction between Sildenafil citrate and excipients. In vitro drug release study was 
carried out with Franz diffusion cell using cellophane membrane in pH 7.4 phosphate 
buffers as diffusion medium. Formulation batch containing carbopol 934P and PEG 
400 permeation enhancer showed 99.20 % drug release at 180 min and 7.98 g.cm /sec 
spreadability. Stabilitystudies conducted under accelerated condition were shown 
satisfactory results. It was concluded that carbopol gel containing Sildenafil citrate 
showed good consistency, spreadability, homogeneity and stability61. 
 
S.B.Ahire et al., (2012) Taste is an important parameter in administering drugs orally 
and is a critical factor to be considered while formulating orodispersible, melt in 
mouth, buccal tablet and other formulations which comes in contact with taste buds. 
Good flavor and texture are found to significantly affect sell of the product. 
Undesirable taste is one of the important formulation problems encountered with most 
of the drugs. Taste masking technologies offer a great scope for invention and patents. 
Several approaches like adding flavors and sweeteners, use of lipoproteins for 
inhibiting bitterness, numbing of taste buds, coating of drug with inert agents, 
microencapsulation, multiple emulsion, viscosity modifiers, vesicles and liposomes, 
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prodrug formation, salt formation, formation of inclusion and molecular complexes, 
solid dispersion system and application of ion exchange resins have been tried by the 
formulators to mask the unpleasant taste of the bitter drugs. The present review 
attempts to give a brief account of different technologies of taste masking with respect 
to dosage form and novel methods of evaluation of taste masking effect62.  
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3. AIM AND OBJECTIVE 
 
The main aim and objective of this study is to formulate and evaluate chewable 
tablet of taste masking sildenafil citrate.  
3.1. REASON FOR SELECTION OF CHEWABLE TABLETS OF TASTE 
MASKING SILDENAFIL CITRATE 
Clinically selective inhibitor of phosphodiesterase type 5 enzymes (PDE5) is 
extensively used for the treatment of erectile dysfunction. Conventional sildenafil 
citrate tablet available in the marked are not suitable where onset of action is slow. 
Thus chewable tablet achieve high bioavailability and rapid onset of action. 
Particularly one that disintegrates and dissolves or disperses in saliva and 
administered without need of water. It has unacceptable taste and present study to 
formulate the chewable tablet with taste masked. My attempt was made in the present 
work to formulate and evaluate chewable tablet of sildenafil citrate. 
 
"Generally, in man, oral administration of the phospho diesterase inhibitors is 
the preferred route, being the most convenient and avoiding the disadvantages 
associated with intra cutaneous administration. Phospho diesterase inhibitors include 
drugs such as Sildenafil Citrate and they are available in the market in form of a film-
coated tablet, wherein, film-coating has to dissolve and tablet has to disintegrate into 
granules and further the drug has to release for dissolution in acidic media of stomach. 
Normal mouth dispersible tablets release the drug for absorption in oral cavity. 
Further Sildenafil is very bitter to taste PDE inhibitors. Hence formulation 
development is very critical. Effectiveness of any phospho diesterase inhibitor 
formulation will depend upon initial complexation to the extent necessary to bypass 
taste buds without detection with the ability to subsequently release the drug from the 
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complex after pH adjustment in digestive tract. Dispersible tablets are the 
formulations that elude the process of disintegration that occurs with conventional 
formulation, dispersible tablets are formulated to make the drug product bio-available 
at a faster rate for immediate action.  
 
In the present study of sildenafil citrate was designed, for the following reasons. 
 Sildenafil citrate pure drugs are bitter taste. Ph-modification method. Higher 
dosage forms are administered into the chewable tablet form. Prevent from into 
the first pass metabolism. High solubility and high permeability. 
 Sildenafil citrate is used in the treatment of erectile dysfunction and also used 
into the pulmonary hypertension. Sildenafil citrate has a vasodilator properties 
resulting in mild and transient decrease in the blood pressure. Quick on set of 
action. 
MORINGA OLEIFERA: 
Moringa oleifera is a small genus of quick growing tree distributed in India. 
The stem of the tree exudes a gum which is initially white in colour but changes to 
reddish brown or brownish black on exposure to sunlight. It is sparingly soluble in 
water but swells in contact with water giving a highly viscous solution. Moringa 
oleifera gum Binder and release retardant in tablet. Binders are agents used to 
cohesive quality to the material during the production of the tablet. They import 
cohesiveness of the tablet formulation. Which ensures that the tablet remain intact 
after compression as well as improving the free flowing quality. Binders have been 
used as the solution in the formulation and the method of preparation. The choice of a 
particular binding agent depends on the binding force required to form the granules 
and compatability with the other ingredients particularly the active drug. It is 
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polyuronide consisting of arabinose, galactose and glucoronic acid in the proportion 
of 10:7:2, rhamnose is present in traces. It was observed that drug release increased 
with increasing proportions of the excipient and decreased proportion of the gum. 
Gum was also studied for its disintegrating property. Different batches of tablets were 
formulated varying them by quantity of the gum. It was observed that wetting time 
decreased with the increase in concentration of gum in formulation. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
PLAN OF WORK 
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3.2 PLAN OF WORK 
The present work was carried out to formulate development and evaluate the 
chewable tablet by taste masking of sildenafil citrate. 
 Chewable tablet prepared by direct compression method.  
 Mannitol is widely used as excipients in chewable tablet for its non-hygroscopic 
nature for moisture sensitive drug. 
 Using artificial sweeteners may provide a satisfactory alternative.  
 Taste masking method using dried calcium carbonate different concentration ratio. 
Taste masking method was performed by Ph-Modification method.  
 Adjustment of pH Values: Many drugs are less soluble at pH different from the 
pH value of the mouth, which is around 5.9. Solubilization inhibitor, such as 
sodium carbonate, sodium bicarbonate, sodium hydroxide, or calcium carbonate, 
was added to increase the pH when granules’ including a sildenafil citrate-
dissolved in aqueous medium, the bitter taste of the drug was successfully masked 
by a sweetener alone. 
 Performing in Drug-Excipients compatibility studies by IR studies. 
3.2.1. Physic-chemical evaluation of the chewable tablet.  
• Preformulation studies 
• Evaluation of blend 
• Angle of repose 
• Bulk density 
• Tapped density 
• Compressibility index 
• Hausner’s ratio 
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3.2.2. Evaluation of chewable tablet 
• Weight variation. 
• Hardness 
• Friability 
• Thickness 
• Drug content 
•  disintegration time 
• Wetting time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                       
 
 
CHAPTER 4 
DRUG AND EXCIPIENT 
PROFILE 
 
 
 
 
4. DRUG AND EXCIPIENTS PROFILE 
 
4.1 Drug profile.27 
4.1.1. Identification: 
4.1.1.1. Drug name: sildenafil citrate 
4.1.1.2. Structure: 
  
4.1.1.3. Chemical formula : C28H38N6O11S 
4.1.1.4. Molecular weight    : 666.703g/mol 
4.1.1.5. Melting point          : 189-190 °C 
4.1.1.6. Dose             : 25mg, 50mg, 100mg 
4.1.1.7. Type                         : Small molecule 
4.1.1.8 .Category                  : Erectile dysfunction, pulmonary hypertension 
4.1.1.9. Description              : white to almost white, crystalline powder. It aqueous  
 solubility is equivalent to 2.6mg sildenafil per ML              
at 250c. 
4.1.1.10. Route of administration:  oral route, Transdermal gel 
4.1.1.11. BCS classification          : Class-I 
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4.1.2. Storage: Store below 300c 
4.1.3.Mechanism of action: Sildenafil citrate inhibits the cGMP-specific 
phosphodiesterase type 5 (PDE5) which is responsible for degradation of cGMP in the 
corpus cavernosum located around the penis. penile erection during the period of 
sexual stimulation is caused by increased penile blood flow resulting from the 
relaxation of penile arteries and corpus smooth muscle. This response has mediated 
the synthesis of cGMP in smooth muscle cells .cyclic GMP causes smooth muscle 
relaxation and increased blood flow into the corpus cavernosum. The inhibition of 
phosphodiesterase type 5 (PDE %) by sildenafil enhances erectile function by 
increasing the amount of cGMP>90%absorbed with ~40% reaching circulation into 
the following first pass metabolism. 
 
4.1.4. Taxonomy:  
4.1.4.1. Kingdom                 : Organic 
4.1.4.2. Classes                     : Phosphodiesterase type-5 
4.1.5. Pharmacokinetic profile:- 
4.1.5.1. Absorption: - >90% absorbed with ~40% reaching systemic circulation 
unchanged following first pass metabolism. 
 
4.1.5.2. Protein binding:  96% Sildenafil appears to be completely metabolized in the 
liver to 16 metabolites. Its metabolism is mediated mainly by cytochrome P450 
microsomal isozymes 3A4 (major route) and 2C9 (minor route). The major circulating 
metabolite, N-demethylated metabolite, has PDE selectivity similar to the parent drug 
and ~50% of it's in vitro potency. The N-demethylated metabolite is further 
metabolized to an N-dealkylated N, N-de-ethylated metabolite. Sildenafil also 
undergoes N-dealkylation followed by N-demethylation of the piperazine ring. 
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4.1.5.3. Half life                 : - 4hours 
4.1.5.4. Metabolism           : - Hepatic. 
4.1.5.5. Excretion              : - lesser extent in the urine (approximately 13% of the  
administered oral dose).   
4.1.5.6. Adverse effect: - A headache, urinary tract infection, diarrhea, Cardiac 
death, myocardial infection. 
4.1.5.7. Therapeutic use: - it’s used in the treatment of erectile dysfunction, and 
pulmonary hypertension. 
4.2. Excipient Profile. 
4.2.1. Calcium carbonate28 
4.2.1.1. Non-Proprietary Name:-  
BP  :  calcium carbonates (1:1) 
JP  :  carbonic acid calcium salt (1:1) 
PHEUR :  calcium carbonate 
USP  :  calcium carbonate 
4.2.1.2. Synonyms:- 
Cali carbons: calcium carbonates (1:1); precipitated carbonate   lime; 
precipitated chalk; 
4.2.1.3. Chemical name:- 
Carbonic acid: calcium salt; 
4.2.1.4. Empirical formula and molecular weight:- 
                                      Caco3, 100.9         
 
 
               
4.2.1.5. Structure Formula:- 
     
4.2.1.6. Functional category: 
Buffering agent, coating agent, opacifiers, tablet binders, tablet diluents, 
therapeutic agents. 
4.2.1.7. Application in pharmaceutical formulation or technology:- 
Mainly used solid-dosage forms of diluents. Dissolution aid in dispersible 
tablets.caco3 bulking agents. Tablets sugar coating on opacifier in film coating tablets. 
4.2.1.8. Typical properties:- 
Density bulk  : 0.8kg/cm3 
Floability  :  cohesive 
Hardness  :  3.0kg/cm3  
Refractive index :  1.59 
4.2.1.9. Stability and storage conditions:- 
Calcium carbonate is stable and should be stored in well-closed containers. 
4.2.2. Polyvinyl Pyrolidine k.3029 
4.2.2.1. Synonym: - PVP 
4.2.2.2. Chemical Name: 
POLYVINYL PYROLIDINE K 30 
4.2.2.3. Molecular formula: - (-CH (NCH2CH2CH2CO) CH2-) n 
 
 
4.2.2.4. Structure:- 
 
4.2.2.5. Functional category:- 
Clarifying agents; stabilizers 
4.2.2.6. Application:-  
Clarifying agents; stabilizers; thickeners agent; tablet fillers; dispersants; PVP 
of molecular weight 360,000 are often used as the clarifying agent of beer, vinegar, 
and grapewine. Used as the fixing liquid for gas chromatography. It is used as a 
colloidal stabilizer and clarifying agent for beer clarification. Apply proper amount 
according the demands of production. It can be used for pharmacy, aquaculture, and 
livestock disinfectant for the sterilization of the skin and mucous.30 
 
4.2.2.7 Storage:- 
Keeped in dry place at the room temperature. 
4.2.3. Crosspovidone31 
4.2.3.1. Non-Proprietary Name:  
BP  : crospovidone 
PHEUR : crospovidone 
   USP-NF : crospovidone 
 
 
4.2.3.2. Synonms:- 
Crospovidone;crosphopham;crosslinkedpovidone;polyvinylpyrolidone; pvpp; 
1-vinyl-2-pyrrolidinone homopolymer. 
4.2.3.3. Chemical Name:- 
  1-ethenyl-2-pyrolidinone homopolymer. 
4.2.3.4. Empirical formula and Molecular Weight:- 
                                      (C6H9N)>1000000 
4.2.3.5. Structure:- 
 
4.2.3.6. Functional category:- 
                                  Tablet disintegrant. 
 
4.2.3.7. Stability and storage conditions:- 
  Povidone darkens to some extent on heating at 1500c, with a reduction in 
aqueous solubility. It is stable to a short cycle of heat exposure around                   
110-1300c,steam sterilization of an aqueous solution dose not alter its properties. 
Aqueous solution is susceptible to mold growth and consequently require the addition 
of suitable preservatives. Povidone may be stored under ordinary conditions without 
undergoing decomposition or degradation. However, since the powder is hygroscopic, 
it should be stored in an airtight container in a cool, dry place.28 
 
46 
 
4.2.3.8. Application in pharmaceuticals:- 
Since crospovidone is water insoluble tablet disintegrant and dissolution agent 
used 2-5%concentration tablet prepared by direct compression or wet and dry –
granulation method. Crospovidone can be used enhance the solubility of the poorly 
soluble drug. 
4.2.3.9. Description:- 
Povidone occurs as a fine, white to creamy-white colored, odorless or almost 
odorless, hygroscopic powder. Povidone with K-values equal to or lower than 30 are 
manufactured by spray-drying and occur as spheres. Povidone K-90 and higher K-
value povidone are manufactured by drum drying and occur as plates. 
4.2.3.10. Incompatibilities:- 
Povidone is compatible in solution with a wide range of inorganic salts, 
natural and synthetic resins, and other chemicals. It forms molecular adducts in 
solution with sulfathiazole, sodium salicylate, salicylic acid, Phenobarbital, tannin, 
and other compounds. The efficacy of some preservatives, e.g. Thimerosal, may be 
adversely affected by the formation of complexes with povidone.  
 
4.2.4. Cross carmellose sodium 
4.2.4.1. Nonproprietary Name: - Croscarmellose sodium 
4.2.4.2. Synonyms:-  
Ac-di-sol; carmellosum natricum conexum; Crosslinked 
carboxymethylcellulose sodium; Explocel: modified cellulose gum; Nymcel ZSX; 
Pharmacel XL; Primellose;   
4.2.4.3. Chemical Name:- 
Cellulose, carboxymethyl ether. 
 
4.2.4.4. Molecular Weight:- 
90000-700000 
4.2.4.5. Structural Formula:- 
 
4.2.4.6. Functional Category:- 
Tablet and capsule disintegrant. 
4.2.4.7. Description:-  
Croscarmellose sodium occurs as an odorless, white or grayish-white powder.  
4.2.4.8. Solubility:-  
Insoluble in water, although Croscarmellose sodium rapidly swells to 4-8 
times its original volume on contact with water. Practically insoluble in acetone, 
ethanol, and toluene32 
4.2.4.9. Stability and Storage Conditions:-  
Croscarmellose sodium is a stable though the hygroscopic material. A model 
tablet formulation prepared by direct compression, with Croscarmellose sodium as a 
disintegrant, showed no significant difference in drug dissolution after storage at 
3000C for 14 months. Croscarmellose sodium should be stored in a well-closed 
container in a cool, dry place.  
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4.2.4.10. Incompatibilities:-  
The efficacy of disintegrant such as Croscarmellose sodium may be slightly 
reduced in tablet formulations prepared by either the wet-granulation or direct 
compression process that contain hygroscopic excipients such as sorbitol. 
Croscarmellose Sodium is not compatible with strong acids or with soluble salts of 
iron and some other metals such as aluminum, mercury, and zinc.  
4.2.4.11. Applications:-  
Croscarmellose sodium is used in oral pharmaceutical formulations as a 
disintegrant for capsules, tablets, and granules. In tablet formulations, Croscarmellose 
sodium may be used in both direct-compression and wet-granulation processes. When 
used in wet granulations, the Croscarmellose sodium should be added in both the wet 
and dry stages of the process (intra and extra- granularly) so that the wicking and 
swelling ability of the disintegrant are best utilized. Croscarmellose sodium at 
concentrations up to 5% w/w may be used as tablet disintegrant, although normally 
2% w/w is used in tablets prepared by direct compression and 3%w/w in tablet 
prepared by wet granulation process.  
4.2.4.12. Related Substances: -   
Carboxy methyl cellulose calcium: Carboxy methyl cellulose sodium 
4.2.5. Mannitol33 
4.2.5.1. Nonproprietary Names:- 
•  BP : Mannitol 
• JP : D-Mannitol 
• PHEUR: Mannitolum 
• USP :Mannitol 
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4.2.5.2. Synonyms:-  
Cordycepic acid, E421, manna sugar, D-mannite, mannite, Mannogem, 
pearlitol.             
4.2.5.3. Chemical Names:- 
D-Mannitol 
4.2.5.4. Empirical formula and Molecular Weight:- 
C6H14O6. 182.17 
4.2.5.5. Functional Category:- 
Diluent, diluents for lyophilized preparations, sweetening agent, tablet and 
capsule diluents, tonicity agent. 
4.2.5.6. Applications in Pharmaceuticals Formulation or Technology:- 
Mannitol is widely used in pharmaceutical formulations and food products. In 
pharmaceutical preparations it is primarily used as a diluent (10 – 90% w/w) in tablet 
formulations, where it is of particular value since it is not hygroscopic and may thus 
be used with moisture-sensitive active ingredients. Mannitol may be used in direct-
compression tablet applications, for which the granular and spray-dried forms are 
available, or in wet granulations. Granulations containing mannitol have the 
advantage of being dried easily. Specific tablet applications include antacid 
preparations, glycerly trinitrate tablets, and vitamin preparations. Mannitol is 
commonly used as an excipient in the manufacture of chewable tablet formulations 
because of its negative heat of solution, sweetness, and ‘mouth feel’. In lyophilized 
preparations, mannitol (20-90% w/w) has been included as a carries to produce a stiff, 
homogeneous cake that improves the appearance of the lyophilized plug in a vial. A 
pyrogen-free form is available specifically for this use34. 
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Mannitol has also been used to prevent thickening in aqueous antacid 
suspensions of aluminum hydroxide (<7% w/v).It has been suggested as a plasticizer 
in soft-gelatin capsules, as a component of sustained-release tablet formulations, and 
as a carries in dry powder inhalers. It is also used as diluents in rapidly dispersing oral 
dosage forms. It is used in food applications as a bulking agent. 
 
   Therapeutically, mannitol administered parenterally is used as an osmotic 
diuretic, as a diagnostic agents for kidney function,as an adjunct in the treatment of 
acute renal failure, and as an agent to reduce intracranial pressure, treat cerebral 
edema, and reduce intraocular pressure .given orally, mannitol is not absorbed 
significantly from the GI tract, but in large doses it can cause osmotic diarrhea.  
   
4.2.5.7. Description:- 
 Mannitol is D-Mannitol.it is a hexahydric alcohol related mannose and is 
isomeric with sorbitol.Mannitol occurs as a white, odourless, crystalline powder, or 
free-flowing granules. It has a sweet taste, approximately as sweet as glucose and half 
as sweet as sucrose, and imparts a cooling sensation in mouth. Microscopically, it 
appears as orthorhombic needles when crystallized from alcohol.         
 
4.2.5.8. Stability and storage conditions:- 
Mannitol is stable in the dry state and in aqueous .solutions may be sterilized 
by filtration or by autoclaving and if necessary may be autoclaved repeatedly with no 
adverse physical or chemical effects. In solution, mannitol is not attacked by cold, 
dilute acids, alkali, or by atmospheric oxygen in the absence of catalysts. Mannitol 
does not undergo maillaard reaction. The bulk material should be stored in a well-
closed container in a cool, dry place. 
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4.2.5.9. Incompatibilities:- 
Mannitol solutions, 20%w/v or stronger, may be salted out potassium chloride 
or sodium chloride. Precipitation has been reported to occur when a 25%w/v mannitol 
solution was allowed to contact plastic. Sodium cephapirin at 2 mg/ml and 30 mg/ml 
concentration is incompatible with 20% w/v aqueous mannitol solution. Mannitol is 
incompatibilities with xylitol infusion and may from complexes with some metals 
such as aluminum, copper, and iron. Reducing sugar impurities in mannitol have been 
implicated in the oxidative degradation of a peptide in a lyophilized formation. 
Mannitol was found to reduce the oral bioavailability of cimetidine compared to 
sucrose.                     
4.2.6. Aspartame35 
4.2.6.1 Non-Proprietary Name:-  
                                               BP: aspartame 
                                          PHEUR: aspartame 
         USP-NF: aspartame      
4.2.6.2. Synonyms:-  
(3S)-3-Amino-4-[[(1S)-1-benzyl-2-methoxy-2-oxoethyl] amino]-4- 
Oxobutanoic acid; 3-amino-N-(a-carboxyphenethyl) succinamic 
Acid N-methyl ester; 3-amino-N-(a-methoxycarbonylphenethyl)- 
Succinamic acid; APM; aspartame; aspartyl phenyl amine methyl 
4.2.6.3. Chemical name:- 
                                      N-L-a-Aspartyl-L-phenylalanine 1-methyl ester. 
4.2.6.4. Empirical formula and molecular weight:- 
                                   C14H18N2O5        294.30 
 
4.2.6.5. Structure:- 
 
4.2.6.6. Functional category: 
Sweetening agents. 
4.2.6.7. Application: 
Aspartame is used as an intense sweetening agent in beverage products, food 
products, and table-top sweeteners, and in pharmaceutical preparations including 
tablets,(1,2) powder mixes, and vitamin preparations. It enhances flavor systems and 
can be used to mask some unpleasant taste characteristics; the approximate 
sweetening power is 180–200 times that of sucrose. Unlike some other intense 
sweeteners, aspartame is metabolized in the body and consequently has some nutritive 
value: 1 g provides approximately 17 kJ (4 kcal). However, in practice, the small 
quantity of aspartame consumed provides minimal nutritive agents36. 
4.2.6.8. Description: 
Aspartame occurs as an off white, almost odorless crystalline Powder with an 
intensely sweet taste. 
                      Density (true) 1.347 g/cm3 
                      Effective angle of internal friction 43.08(3) 
                        Melting point 246–2478C 
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4.2.6.9. Stability and Storage Conditions: 
Aspartame is stable in dry conditions. In the presence of moisture, Hydrolysis 
occurs to form the degradation products L -aspartyl-L phenylalanine And 3-benzyl-6-
carboxymethyl-2,5-diketopiperazine with a resulting loss of     sweetness. A third-
degradation product is also known, b-L-asparty phenylalanine methyl ester. For the 
stability profile at 258C in aqueous buffers. 
4.2.7.  Aerosil 
4.2.7.1. Nonproprietary Names:- 
BP: Colloidal Anhydrous Silica 
JP: Light Anhydrous Silicic Acid 
PhEur: Silica, Colloidal Anhydrous 
USP-NF: Colloidal Silicon Dioxide 
4.2.7.2. Synonyms:- 
Aerosil; Cab-O-Sil; Cab-O-Sil M-5P; colloidal silica; fumed silica; 
Fumed silicon dioxide; hochdisperses silicum dioxid; SAS; silica 
Colloidalis anhydrica. 
4.2.7.3. Chemical name:- 
Silica 
4.2.7.4. Empirical Formula and Molecular weight:- 
Sio2 60.08 
4.2.7.5. Functional Category:- 
Adsorbent; anticaking agent; emulsion stabilizer; glidant; suspending agent; 
tablet disintegrant; thermal stabilizer; viscosity-increasing agent. 
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4.2.7.6. Application in pharmaceutical Formulation or Technology:- 
Colloidal silicon dioxide is widely used in pharmaceuticals, cosmetics, and 
food products;  Its small particle size and large specific surface area give it desirable 
flow characteristics that are exploited to improve the flow properties of dry powders 
in a number of processes such as tableting and capsule filling. Colloidal silicon 
dioxide is also used to stabilize emulsions andas a thixotropic thickening and 
suspending agent in gelsandsemisolid preparations.With other ingredients of similar 
refractive index, transparent gels may be formed. The degree of viscosity increase 
depends on the polarity of the liquid (polar liquids generally require a greater 
concentration of colloidal silicon dioxidethan nonpolar liquids). Viscosity is largely 
independent of temperature. However, changes to the pH of a system may affect the 
viscosity; In aerosols, other than those for inhalation, colloidal silicon dioxide is used 
to promote particulate suspension, eliminate hard settling, and minimize the clogging 
of spray nozzles. Colloidal silicon dioxide is also used as a tablet disintegrant and as 
an adsorbent dispersing agent for liquids in powders. Colloidal silicon dioxide is 
frequently added to suppository formulations containing lipophilic excipients to 
increase viscosity, prevent sedimentation during molding, and decrease the release 
rate. Colloidal silicon dioxide is also used as an adsorbent during the preparation of 
wax microspheres; as a thickening agent for topical preparations; and has been used to 
aid the freeze-drying of nanocapsules and nanosphere suspensions.37 
Aerosols-concentration 0.5-2.0 
Emulsion stabilizer-1.0-5.0 
Glidant-0.1-0.5 
Suspending agent-2.0-10.0 
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4.2.7.7. Description:- 
Colloidal silicon dioxide is submicroscopic fumed silica with a particle size of 
about 15 nm. It is a light, loose, bluish-white-colored, odorless, tasteless, amorphous 
powder. 
4.2.7.8. Stability and Storage Conditions:- 
Colloidal silicon dioxide is hygroscopic but adsorbs large quantities of water 
without liquefying. When used in aqueous systems at a pH 0–7.5, colloidal silicon 
dioxide is effective in increasing the viscosity of a system. However, at a pH greater 
than 7.5 the viscosity increasing properties of colloidal silicon dioxide are reduced; 
and at a pH greater than 10.7 this ability is lost entirely since the silicon dioxide 
dissolves to form silicates. Colloidal silicon dioxide powder should be stored in a 
well-closed container.38 
4.2.7.9. Incompatibilities:- 
Incompatible with diethylstilbestrol preparations 
4.2.8. Talc 
4.2.8.1. Synonyms:- 
Altalc, E553b, hydrous magnesium calcium silicate, hydrous magnesium 
silicate, Luzenac phrama, magnesium hydrogen metasilicate, Magsil Osmanthus, 
Magsil star, powdered talc, purified French chalk,Purtalc, soapstone, superior. 
4.2.8.2. Empirical Formula and molecular Weight:- 
Talc is purified, hydrated, magnesium silicate, approximating to the formula  
Mg6 (Si2O5)4(OH)4. It may contain small, variable amounts of aluminum silicate and 
iron. Molecular weight is 260.8617 
4.2.8.3. Structural Formula:- 
  Mg3Si4O10 (OH) 2 
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4.2.8.4. Functional Category:- 
Anti caking agent, glidant, tablet and capsule diluents, tablet and capsule 
lubricant. 
4.2.8.5. Applications in Pharmaceutical Formulation or Technology:- 
Talc was once widely used in oral solid dosage formulation as a lubricant and 
diluents, although today it is less commonly used. However, it is widely used as a 
dissolution retardant in the development of controlled-release products. Talc is also 
used as a lubricant in tablet formulations, in a novel powder coating for extended-
release pellets, and as an adsorbent. In topical preparations, talc is used as a dusting 
powder, although it should not be used to dust surgical gloves. Talc is a natural 
material; it may therefore frequently contain microorganisms and should be sterilized 
when used as a dusting powder.39 
• Dusting powder –concentration (90.0-99.0%) 
• Glidant and tablet lubricant-1.0-10.0 
• Tablet and capsule diluents-5.0-30.0 
4.2.8.6. Description:- 
Talc is a very fine, white to grayish-white, odorless, impalpable, unctuous, 
crystalline powder. It adheres readily to the skin and is soft to the touch and free from 
grittiness. 
 
4.2.8.7. Incompatibilities:- 
 Incompatible with quaternary ammonium compounds.    
4.2.9. Starch 
4.2.9.1. Non-proprietary Name:- 
                                BP: Maize starch 
    JP: Corn Starch 
         PhEur: Maize Starch 
4.2.9.2. Synonyms:- 
Amido; amidon; amilo; amylum; PharmGel; Eurylon; fecule; Hylon; maydis 
amylum; Melojel; Meritena; oryzae amylum; 
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4.2.9.3. Empirical formula and molecular weight:- 
(C6H10O6)nwhere n = 300–1000. 
4.2.9.4. Functional category:- 
Tablet and capsule diluent; tablet and capsule disintegrant;     tabletbinder; 
thickening agent. 
4.2.9.5. Application in pharmaceuticals 
Starch is a versatile excipient used primarily in oral solid-dosageformulations 
where it is utilized as a binder, diluent, anddisintegrant.As a diluent, starch is used for 
the preparation of standardized triturates of colorants, potent drugs, and herbal 
extracts, facilitating subsequent mixing or blending processes in manufacturing 
operations.Starch is also used in dry-filled capsule formulations forvolume adjustment 
of the fill matrix,and to improve powder flow, especially when using dried starches. 
Starch quantities of 3–10% w/w can act as an antiadherent and lubricant in tableting 
and capsule filling. In tablet formulations, freshly prepared starch paste is used at a 
concentration of 3–20% w/w (usually 5–10%, depending on thestarch type) as a 
binder for wet granulation. The required binder ratio should be determined by 
optimization studies, using parameters such as tablet friability and hardness, 
disintegration time, and drug dissolution rate. Starch is one of the most commonly 
used tablet disintegrants at concentrations of 3–25% w/w. 
4.2.9.6. Description:- 
Starch occurs as an odorless and tasteless, fine, white to off-white powder. It 
consists of very small spherical or ovoid granules or grains whose size and shape are 
characteristic for each botanical variety. 
 
 
58 
 
4.2.9.7. Stability conditions:- 
Dry starch is stable if protected from high humidity. Starch is Considered to be 
chemically and microbiologically inert under both amylose and amylopectin have 
been evaluated as safe and without limitation for daily intake. Contamination of 
surgical wounds with the starch glove powder used by surgeons has resulted in the 
development of granulomatouslesions. 
4.2.10.8. Incompatibility:- 
Starch is incompatible with strongly oxidizing substances. Colored inclusion 
compounds are formed with iodine. 
4.2.10.9. Safety:- 
Starch is an edible food substance, considered a food ingredient and not a food 
additive. It is regarded as an essentially nontoxic and nonirritant material. Starch is 
therefore widely used as an excipient in pharmaceutical formulations.  
   4.2.10. Citric acid monohydrate40 
4.2.10.1. Non-Proprietary Name:-      
BP : citric acid mono hydrate. 
JP : citric acid hydrate. 
PHEUR: citric acid mono hydrate. 
USP : citric acid mono hydrate. 
4.2.10.2. SYNONMS:-  
       Acidum citricum monohydricum; 1, 2, 3 tri carboxylic acid. 
4.2.10.3. Chemical name:- 
         2-hydroxy- 1, 2, 3 propanetric carboxylic acid mono hydrate 
4.2.10.4. Empirical formula and molecular weight:- 
                                          C6H8O7.H2O    210.14 
4.2.10.5. Structural formula:- 
 
 
4.2.10.6. Functional category:- 
Acidifying agent; antioxidants; buffering agents; chelating    agents; flavoring 
agents. 
4.2.10.7. Application:- 
  Widely used in pharmaceutical formulations and food products; primarily 
adjust the PH of the solutions. It also used in the experimental for the tablets PH 
adjust and also using tablets material in enteric coating tablets in the colon specific 
drug delivery systems. Citric acid used in the flavors’ enhancers for it acidic taste. 
4.2.10.8. Stability and storage conditions:- 
 Citric acid mono hydrate is a loss of water for crystallization in dry air. 
When heated at about 400c.it slightly deliquescent in moist air .dilute aqueous solution 
of the citric acid may be ferment on standing.41 
4.2.10.9. Description:- 
 Citric acid monohydrate is translucent crystals, or white crystalline, 
efflorescent powders. It is an odorless and strong acidic taste. 
4.2.10.10. Typical properties: - 
  Density: 1.542g/cm3 
  Hygroscopicity: AT relative humidity at 250c.the bulk monohydrate 
and anhydrous materials at the store at air tight containers and store in cool place. 
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4.2.10.11. Methods of manufacture:- 
  Citric acid occurs naturally in a number of plant species and may be 
extracted from lemon juice, which contains 5–8% citric acid Pineapple waste. 
Anhydrous citric acid may also be produce industrially by mycological fermentation 
of crude sugar solutions Such as molasses, using strains of aspergillums Niger. Citric 
acid is purified by recrystallization; the anhydrous form is obtained from a hot 
concentrated aqueous solution and the monohydrate from a Cold concentrated 
aqueous solution. 
4.2.11. Magnesium stearate:- 
4.2.11.1. Synonyms:- 
 Magnesium octadecanoate; Octadecanoic acid, magnesium Salt; Stearic 
acid, magnesium salt. 
4.2.11.2. Chemical Name:- 
 Octadecanoic acid magnesium salt. 
4.2.11.3. Molecular Formula:- 
 C36H18N2505 
4.2.11.4. Molecular weight:- 
 591.34 
4.2.11.5. Functional category:- 
 Tablet and capsule lubricant.  
4.2.11.6. Application in pharmaceutical Formulation or Technology:- 
It is widely used in cosmetics, food and pharmaceutical Formulation. It is 
primarily used as a lubricant in capsule in barrier creams. And tablet manufacture at 
concentrations between 0.25% and 5.0% w/w. 
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4.2.11.7. Stability and Storage:-  
It is stable and should be stored in a well-closed container In a cool, dry place. 
4.2.11.8. Incompatibilities:-          
Incompatible with strong acids, alkalis, and iron salts. Avoid mixing with 
strong oxidizing materials. It cannot be used in products containing aspirin, some 
vitamins, and most alkaloid salts. 
4.2.11.9. Safety:-                
Nontoxic following oral administration. However, oral Consumption of large 
quantities may produce a laxative Effect or mucosal irritation.42 
    
  
 
 
CHAPTER 5 
MATERIALS AND METHODS 
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5.1 MATERIALS AND METHODS 
  
The Materials used in the present work are as follows.   
  
S NO Materials Name of the supplier 
1. Sildenafil citrate Chandra labs, hyd 
2. Dried calcium carbonate MYL CHEM MUMBAI 
3. Oyster Calcium Carbonate Chandra labs, hyd 
4. PvP k30 MYL CHEM Mumbai 
5. Crospovidone MYL CHEM Mumbai 
6. Croscarmellose sodium MYL CHEM Mumbai 
7. Mannitol S.D Fine Chem. LTD Mumbai 
8. Aspartame S.D Fine Chem. LTD Mumbai 
9. Lemon flavor MYL CHEM Mumbai 
10. Peppermint flavor MYL CHEM Mumbai 
11. Sunset yellow lake MYL CHEM Mumbai 
12. Aerosil S.D Fine Chem. LTD Mumbai 
13. Talc MYL CHEM MUMBAI 
14. Magnesium stearate Chandra, labs hyd 
15. Citric acid monohydrate S.D FINE CHEM.LTD. 
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5.2 MATERIALS AND METHOD 
 The Materials used in the present work are as follows.   
S. NO. Materials Name of the supplier 
1. Sildenafil citrate Chandra labs, hyd 
2. Dried Calcium carbonate Chandra labs, hyd 
3. Moringa gum Local Nursery 
4. Aerosil MYL CHEM Mumbai 
5. Starch MYL CHEM Mumbai 
6. Mannitol S.D Fine Chem. LTD Mumbai 
7. Citric acid monohydrate S.D Fine Chem. LTD Mumbai 
8. Lemon flavor MYL CHEM Mumbai 
9. Peppermint flavor MYL CHEM Mumbai 
10. Sunset yellow lake MYL CHEM Mumbai 
11. Talc S.D Fine Chem. LTD Mumbai 
12. Magnesium strearate MYL CHEM MUMBAI 
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5.3. Equipment 
 The equipment used in the present work are as follows 
 
S.no Instruments Source 
1 Electronic balance Shimadzu  japan 
2 UV/Visible Spectrophotometer Corporation-BL-220H 
3 FTIR spectrophotometer Corporation Japan 
4 Dissolution apparatus Shimadzu  japan 
5 Hot Air Oven Biotech India. 
6 Compression  machine Cadmach machinery 
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5.1.1. METHODOLOGY 
5.1.1.1. Preformulation studies 
5.1.1.2. Construction of standard graph of   sildenafil citrate in 0.01N HCL. 
5.1.1.3. Preparation of 0.01N HCL. 
1. Take 8.5ml of Conc.HCl in distilled water and makeup to 10000ml with distilled 
Water to get 0.01N HCl43. 
2. Construction of standard graph of sildenafil citrate in 0.01n hcl. 
3. Preparation of stock solution. 
a. The accurately weighed amount of 30 mg was transferred into a 100ml volumetric 
flask. And the volume was made up to 50 mL with 0.01N HCl.   
4. Preparation of working standard solution. 
a. From this stock solution, 2.5,4,5,6,7.5 was taken and diluted to 50 mL with 0.01N 
HCl which has given the solution having the concentration of 100 mcg/mL 
5. Preparation of serial dilutions for standard calibration curve. 
Necessary dilutions were made by using this second solution to give the different 
concentrations of sildenafil citrate (2.5,4,5,6,7.5 mcg/mL) solutions. 
The absorbance of above solutions was recorded at λmax (290 nm) of the drug 
using double beam UV-Visible spectrophotometer. A standard graph was plotted 
between the concentration (on X-axis) and absorbance (on Y-axis). 
5.2.1. Drug – excipient compatibility study 
  The IR absorption spectra of the pure drug and with different excipients were 
taken in the range of 4000-500 cm-1 using KBr disc method, 1-2 mg of the substance 
to be examined was triturated with 300-400 mg, specified quantity, of finely 
powdered and dried potassium bromide. These quantities are usually sufficient to give 
a disc of 10-15MM diameter and pellet of suitable intensity by hydraulic press. The 
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infrared spectrum of sildenafil citrate was recorded by using FT-IR spectroscopy and 
observed for characteristic peak of drug, and undisturbed drug structure of the drug, 
which indicates there was no drug.44 
5.2.2. Formulation of chewable tablet (direct compression method) 
The chewable tablets containing 100mg sildenafil citrate were prepared with a 
total tablet weight of 700mg. All the formulations were prepared by direct 
compression.45 
 Procedure 
1. Sildenafil citrate and all other ingredients were individually passed through a 
sieve no.40. 
All the ingredients were mixed thoroughly by triturating up to 15minties. 
2. The powder mixture was lubricated with Magnesium stearate. The tablets were 
prepared by using direct compression method according to the formulation table. 
3. Then the blend was compressed using 13MM Flat beveled edged scored on one 
side 
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Table No: 1 Composition of different formulations for chewable tablet by Direct 
Compression Method 
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9 
Sildenafil citrate 143 143 143 143 143 143 143 143 143 
Calcium 
carbonate(dried) 70 140 210 280 350 -- 350 350 350 
Calcium 
carbonate(oyster 
shell) 
-- -- -- -- -- 350 -- -- -- 
PVP k.30 21 21 21 21 21 21 21 21 21 
Purified water -- -- -- -- -- -- -- -- -- 
Crospovidone -- 15 25 30 35 35 -- 35 -- 
Cros carmellose 
sodium -- 15 25 30 35 35 35 -- -- 
Micro 
Crystalline 
Cellulsoe 
-- --- --- --- --- --- --- --- 35 
Aspartame 16 16 16 16 16 16 16 16 16 
Lemon flavor 7 7 7 7 7 7 7 7 7 
Peppermint 
flavor 4 4 4 4 4 4 4 4 4 
Sunset yellow 
lake 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 
Mannitol 404 304 214 134 54 54 89 89 89 
Aerosil 7 7 7 7 7 7 7 7 7 
Talc 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 
Magnesium 
stearate 7 7 7 7 7 7 7 7 7 
Citric acid 
monohydrate 14 14 14 14 14 14 14 14 14 
Avg.weight total 700mg 700mg 700mg 700mg 700mg 700mg 700mg 700mg 700mg 
  
 
 
 
5.2.3. Chewable tablet (direct compression method) 
 After the batch was optimized and compared with (F5) and (F6). (F6) was 
more compatible with best (F5). (F6) formulation produce tastes masked but grittiness 
formed. The optimized batch in both was compressed by using same ingredients but 
different calcium carbonate (oyster shell).F7-F9 using super disintegrants like 
croscarmellosesodium, crospovidone. 
5.2.4. Formulation of chewable tablet (wet granulation method) 
 The tablets containing 100mg sildenafil citrate were prepared with a total 
tablet weight of 700mg. All the formulations were prepared by wet granulation 
method.43 
5.3.1. Isolation of moringa oleifera gum 
The gum was collected from trees (Injured site). It was dried, ground and passed 
through sieve no 80. Dried gum (10g) was stirred in distilled water (250ml) for 6-8 
hours at room temperature. The supernatant was obtained by centrifugation. The 
residue was washed with water and the washings were added to supernatant. The 
procedure was repeated four times. Finally the supernatant was made up to 500 ml 
and the treated with twice the volume of acetone by continuous stirring. The 
precipitated material was washed with distilled water and dried at 50-60ºC under 
vacuum. 
 
 
 
 
 
Figure no.5 Moringa gum 
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5.3.2. Formulation of tablet 
  The tablets of sildenafil citrate were prepared by wet granulation method using 
Moringa Oleifera gum, dried calcium carbonate as taste masking agent, Starch as 
binder, Purified talc and Magnesium Stearate as lubricant and Aerosil as glidant .citric 
acid monohydrate as adjust  Ph of the solutions. The drug and other ingredients with 
half quantity of disintegrant were mixed together, sufficient quantity of starch paste 
was added to form coherent mass. The wet mass was granulated using sieve No. 40 
and the granules formed were dried into hot Air oven at 40ºC for 20 minutes and 
regranulated using sieve no 20. The granules were blended with remaining quantity of 
the disintegrant (extra granular disintegrant), purified talc, aerosil and compressed 
into 13MM Flat beveled edged scored on one side (Compression machine, 
Ahmedabad, India). 
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Table No: 2 Composition of different formulations for wet granulation method 
Sr. 
No. 
Ingredients 
 
Quantity in mg 
F10 F11 F12 
1. Sildenafil citrate 143 143 143 
2. Dried calcium carbonate 350 350 350 
3. Moringa gum 4 6 8 
4. Starch 15 15 15 
5. Citric acid monohydrate 14 14 14 
6. Aerosil 4 4 4 
7. Lemon flavor 7 7 7 
8. Peppermint flavor 4 4 4 
9. Sunset yellow lake 3.5 3.5 3.5 
10. Mannitol 148.5 146.5 144.5 
11. Talc 4 4 4 
12. Magnesium strearate 3 3 3 
 Avg.weight total 700mg 700mg 700mg 
 
5.4.1. EVALUATION OF PRECOMPRESSION BLEND46 
• Flow Properties: 
• The angle of Repose: 
 The flow property was determined by measuring the Angle of Repose. In 
order to determine the flow property, the Angle of Repose was determined. It is the 
maximum angle that can be obtained between the free standing surface of a powder 
heap and the horizontal. 
Angle of repose= tan-¹ (h/r) 
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Where,  
h = height of a pile (2 cm) 
r = radius of pile base. 
5.4.2. Procedure 
• 20gms of the sample was taken 
• The sample was passed through the funnel slowly to form a heap. 
• The height of the powder heap formed was measured. 
• The circumference formed was drawn with a pencil on the graph paper. 
•   The radius was measured and the angle of repose was determined. This was 
repeated three times for a sample. 
5.4.3. Bulk density 
 Bulk density is the ratio of given mass of powder and its bulk volume. Bulk 
density was determined by measuring the volume of known mass of powder sample 
that has been passed through the screen in to graduated cylinder or through volume 
measuring apparatus into the cup. 
Bulk density = M / V0 
Where M= mass of the powder; 
   The V0=bulk volume of the powder. 
Limits: 
It has been stated that the bulk density values having less than 1.2 g/cm3 
indicates good Packing and values greater than 1.5 g/cm3 indicates poor Packing. 
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5.4.4. Tapped density 
 A known quantity of powder was transferred to a graduated cylinder and volume 
V0 was noted. The cylinder fixed to a density determination apparatus, tapped for 500 times 
than reading was observed. The density is achieved by mechanically tapped by a measuring 
cylinder containing the powder sample. After observing the initial volume the cylinder is 
mechanically tapped and volume reading was taken until little further volume changes are 
observed. 
Tap density = M / Vr 
Where M = mass of the powder,  
  Vr = final tapping volume of the powder. 
5.4.5. Compressibility index and Hauser’s ratio 
The compressibility index and Hausner's ratio may be calculated using 
measured values of bulk density and tapped density as follows: 
Compressibility index = 100 × tapped density / bulk density 
   Hauser’s ratio = tapped density / bulk density 
             Flow properties and corresponding Angle of repose, Compressibility index 
and Hauser’s ratio: 
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Table No: 3 ACCEPTANCE CRITERIA OF FLOW PROPERTIES  
S. No Flow properties 
Angle of  
repose(θ) 
Compressibility
Index (%) 
Hausner’sratio
1. Excellent 25-30 <10 1.00-1.11 
2. Good 31-35 11-15 1.12-1.18 
3. Fair 36-40 16-20 1.19-1.25 
4. Passable 41-45 21-25 1.26-1.34 
5. Poor 46-55 26-31 1.35-1.45 
6. Very poor 56-65 32-37 1.46-1.59 
7. Very very poor > 66 >38 >1.6 
 
5.5.1. Evaluation of tablets 
The quantitative evaluation and assessment of a tablets chemical, physical and 
bioavailability properties are important in the design of tablets and to monitor product 
quality. There are various standards that have been set in the various pharmacopeias 
regarding the quality of pharmaceutical tablets. These include the diameter, size, 
shape, thickness, weight, hardness, Friability and in-vitro dissolution characters. 
5.5.2. Hardness 
The hardness of the tablet was determined by using the Monsanto hardness 
tester. The lower plunger was placed in contact with the tablet and a zero reading was 
taken. The plunger was then forced against a spring by turning a threaded bolt until 
the tablet fractured. As the spring was compressed a pointer rides along a gauge in the 
barrel to indicate the force.47 
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5.5.3. Thickness 
Control of physical dimensions of the tablets such as size and thickness is 
essential for consumer acceptance and tablet-tablet uniformity. The diameter size and 
punch size of tablets depending on the die and punches selected for making the 
tablets. The thickness of tablet is measured by Vernier Callipers scale. The thickness 
of the tablet related to the tablet hardness and can be used an initial control parameter. 
Tablet thickness should be controlled within a ±5%. In addition, the thickness must be 
controlled to facilitate packaging. 
5.5.4. Friability 
Friction and shock are the forces that most often cause tablets to chip, cap or 
break. The friability test is closely related to tablet hardness and designed to evaluate 
the ability of the tablet to withstand abrasion in packaging, handling, and shipping. It 
is usually measured by the use of the Roche friability.48 
Method 
A number of tablets are weighed and placed in the apparatus where they are 
exposed to rolling and repeated shocks as they fall 6 inches in each turn within the 
apparatus. After that rotate the drum at 100 revolutions, the tablets are weighed and 
the weight compared with the initial weight. The loss due to abrasion is a measure of 
the tablet friability. The value is expressed as a percentage. A maximum weight loss 
of not more than 1% of the weight of the tablets being tested during the friability test 
is considered generally acceptable and any broken or smashed tablets are not picked.  
The percentage friability was determined by the formula:  
                                    % friability = (W1-W2) / W1 X 100 
 W1 = Weight of tablets before test  
 W2 = Weight of tablets after test 
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5.5.5. Drug content 
Twenty tablets were selected randomly from each batch, weighed and made 
into a fine powder. The quantity of powder equivalent to 30mg of sildenafil citrate 
was dissolved in 100ml of 0.01NHCL buffer and the resultant solution was filtered 
and filtrate obtained was suitably diluted with the Ph 3 0.01NHcl.sildenafil citrate 
content was determined spectrometrically by measuring the absorbance at 290 nm 
using Shimadzu UV1601 Double beam spectrophotometer. The test was carried out in 
triplicate for all the formulations and the drug content was calculated and reported. 49 
5.5.6. Wetting time: 
Wetting time is closely related to the inner structure of the tablet and to the 
hydrophilicity of the excipients. According to the following equation proposed by 
washburn E.W (1921), the water penetration rate into the powder bed is proportional 
to the pore radius and is affected by hydrophilicity of the powder. 
                                                  Di/dt= rγcos θ/ (4ήl) 
Where I is the length of penetration, r is the capillary radius is the surface 
tension, ή is the liquid viscosity, t is the time, and θ is the time, and θ is the contact 
angle. It is obvious that pore size becomes smaller and wetting time increase with an 
increase in compression force or a decrease in porosity. A linear relationship exists 
between wetting time and disintegration time. Thus wetting is important step for 
disintegration process to place. A place tissues paper folded double was placed in 
Petri dish .(internal diameter is 6.5cm)containing 6ml of water .the tablet was placed 
on the paper ,and the time for complete wetting of the tablet was measured in the 
seconds .the method was slightly modified by maintaining water at 370C.wetting time 
was evaluated .50 
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5.5.7. Disintegration time: 
The disintegration test is carried out in apparatus containing a basket rack 
assembly with six glass tubes of 7.75cm in length and 2.15 mm in diameter, the 
bottom of which Consists of a#10 mesh sieve. The basket is raised and lowered 28-32 
times per minute in a medium of 900ml water which is maintained at 37±2°C. Six 
tablets were placed in each of the tubes and the time required for completer passage of 
tablet fragments through the mesh (#10) was considered as the disintegration time of 
the tablet.49 
5.5.8. Dissolution studies 
5.5.9. In vitro dissolution studies for chewable tablet 
In vitro, drug release studies were carried out using USP XXIV dissolution 
apparatus type II, with 900ml of dissolution medium maintained at 37±1°C for an 
hour, at 100 rpm, 0.01N HCl adjust (PH-3) was used as a dissolution medium. 5ml of 
the sample was withdrawn at predetermined time intervals replacing with an equal 
quantity of drug-free dissolution fluid. The samples withdrawn were filtered through a 
0.45µ membrane filter, and drug release in each sample was analyzed after suitable 
dilution by UV/Vis Spectrophotometer at 290nm. 
 5.6.1. STABILITY STUDIES OF THE TABLET 
Stability of a formulation can be defined as the time from the date of 
manufacture of the formulation until its chemical or biological activity is not less than 
a predetermined level of labeled potency and its physical characteristics have not 
changed appreciably or deleteriously. 
Formulation and the development of a pharmaceutical product are not 
complete without proper stability analysis, carried out on it to assess their physical 
and chemical stability and the safety. The purpose of stability testing is to provide 
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evidence on how the quality of a drug substance of drug product varies with time. 
Under the influence of a variety of environmental factors such as temperature, 
humidity, and light enabling recommended storage conditions, re-tests periods and 
shelf- lives. 
Generally, the observation of the rate at which the product degrades under 
normal room temperature requires a long time. To avoid the undesirable delay, the 
principles of the accelerated stability studies are adapted.  
The international conference on harmonization (ICH) guidelines titled 
“Stability Testing of New Drug Substances and Product” describes the stability test 
requirements for drug registrations application in the European Union, Japan, and the 
USA. ICH specifies the length of study and storage Conditions. 
              Long-Term testing: 25±2◦C/60%±5% RH for 12 months. 
             Accelerated Testing: 40±2◦C/75%±5% RH for 3 months. 
Stability studies for the present work carried out at 40◦C/75%RH for the 
selected formulation (F5) for 3 months. 
Method 
The selective formulations stored at 40◦C/75%RH for 3 months and evaluated 
for their physical appearance and drug content at a specified interval of time. and also 
performed were in vitro dissolution studies. 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 6 
RESULT AND DISSCUSSION 
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6.1. Result and Discussion 
6.1.1. Standard calibration curve of sildenafil citrate 
6.1.2. Concentration and absorbance of sildenafil citrate in 0.01N Hcl  
S.No Concentration[µg/ml] Absorbance at 290nm 
1. 0 0 
2. 50 0.317 
3. 80 0.419 
4. 100 0.599 
5. 120 0.718 
6. 150 0.901 
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Figure no.6.1. Standard calibration curve of Sildenafil citrate 
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Figure no .6.2. I R Spectra of Sildenafil citrate pure drug 
 
 
 
Figure no .6.3. IR Spectra of Sildenafil citrate+ Dried calcium carbonate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure no.6.4.IR spectra of sildenafil citrate + calcium carbonate (oyster shell) 
 
 
 
 
 
 
 
 Figure no.6.5. I R spectra Sildenafil citrate+ pvp k 30 
 
 
 
Figure no .6.6. I R Spectra of Sildenafil citrate+ crospovidone 
 
 
      
Figure no.6.7. I R Spectra of Sildenafil citrate+ croscarmellose sodium 
 
 
 
Figure no. 6.8. I R Spectra of Sildenafil citrate +aspartame 
 
     
 
 
Figure no.6.9. I R Spectra of Sildenafil citrate + Aerosil 
 
 
 
 
 
 
 Figure no.6.10. Sildenafil citrate + blend 
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Table no.4.Sildenafil citrate pure drug peak 
(wave 
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Table no.5.Excipients peak 
(wave number 
cm-1) 1700-2000 1700-2000 2000-2500 2500-3000 3000-3100 
Functional group 
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Table no.6.sildeanfil citrate + blend 
(wave 
number 
cm-1) 
400-
500 
600-
800 
800-
1000 
1000-
1200 
1200-
1400 
1400-
1600 
1600-
1800 
2700-
33000 
3000
-
3700 
2000-
2500 
2500-
3000 
3000-
3200 
 
functional 
group 
 
 
 
 
 
 
 
 
NH 
OH 
 
(CH2)4 
C=C 
C≡C 
AROM
ATIC 
 
=CH 
C=C 
ARO
MATI
C 
 
AROM
ATIC 
PHEN
OL 
ALCO
HOL 
AMINE 
CH3 
AROM
ATIC 
PHEN
OL 
ALCO
HOL 
AMINE 
NO2 
CH3 
AROM
ATIC 
PHEN
OL 
ALCO
HOL 
AMINE 
NO2 
=CH 
C=C 
ARO
MATI
C 
AMI
NE 
C=O 
CH3 
CH2 
CH 
=CH
,C=
C 
Aro
mati
c 
Ami
ne 
keto
ne 
ΞCH,
CΞC 
CN 
CH3 
CH2 
CH 
=CH,C=
C 
Aromatic 
Alcohol 
Phenols 
Amines 
 
 
FT-IR on the selected formulation prepared with different excipients and 
polymer combination. The spectrum peak point of the formulation were similar with 
that of pure sildenafil citrate, it clear indicate that there are no excipients interaction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure no.6.11 sildenafil citrate pure drug 
 
 
 
 
 
 
 
Figure no.6.12 Moringa gum 
 
 
 
 
 
 
 
Figure no.6.13 sildenafil citrate +Moringa gum 
 
 
 
 
 
 
 
 
 Figure no.6.14 sildenafil citrate + All excipients 
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Table no.7.Sildenafil citrate pure drug 
(wave 
number 
cm-1) 
400-
500 
600-800 800-
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1000-1200 1200-1400 1400-1600 1600-
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Table no.8.Moringa gum 
(wave number cm-1) 400-500 1200-1600 2300-2400 2800-3000 3700-4000 
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Table no.9.Sildenafil citrate with moringa gum 
(wave 
number 
cm-1) 
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Table no.10.Sidenafil Citrate with blend  
(wave 
number 
cm-1) 
400-
600 
600-800 800-1000 1000-
1200 
1200-
1400 
1400-1800 2700-3000 3000-3400 
Functional 
Group 
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≡C 
C≡C 
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FT-IR of the formulation and different excipients were prepared with KBr disc 
method. From the Figure 6.2 – 6.14 it was evident that the peak points of the 
formulation were similar with that of pure sildenafil citrate, it clearly indicate that 
there is no interaction of API with the excipients. 
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6.2. Evaluation of pre compression parameters for chewable tablet 
 Table no.11.pre-compression parameters for chewable tablet (direct 
compression) 
 
6.2.1. Angle of repose. 
  All the formulation prepared by direct compression method showed the angle 
of repose between 25o and 29o excellent flow property it show in the above table. 
 
6.2.2. Bulk density, tapped density, compressibility index and hausner’s ratio. 
 The results of , Bulk density, tapped density, compressibility index and 
hausner’s ratio are shown in the table no. 11.The bulk density and tapped bulk density 
for all formulation varied from 0.554 gm/cm3 to 0.574 gm/cm3 respectively. Tapped 
density for all formulation varied from 0.680 to 0.735 gm/cm3. The result of Carr’s 
consolidation index or (%) compressibility index for the entire formulation blend 
Formulation 
code 
Bulk density 
(gm/ml) 
Tapped 
density 
(gm/ml)
Compressibility 
index (%) 
Hausner’s 
ratio 
Angle of 
repose 
F1 0.568 0.693 18.90 1.22 25o.12′ 
F2 0.574 0.726 20.99 1.26 27o.31′ 
F3 0.558 0.680 17.94 1.21 29o.46′ 
F4 0.574 0.765 24.96 1.33 25o.71′ 
F5 0.558 0.680 17.94 1.21 23o.86′ 
F6 0.562 0.685 17.95 1.21 24o.71′ 
F7 0.554 0.710 21.97 1.28 25o.10′ 
F8 0.574 0.735 21.90 1.28 28o.14′ 
F9 0.562 0.702 20.00 1.26 28o.14′ 
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ranged from 17 to 22 shows excellent compressibility index and hausner’s ratio for all 
formulation varied from 1.21 to 1.33 which is an indicative of good flow property.  
6.3. Post compression parameters 
Table no.12.post compression evaluation parameters of chewable tablets 
Formulation 
code 
Average 
weight 
Hardness 
(kg/cm3) 
Thickness 
(mm) 
Friability 
 
disintegratio
n time 
(sec) 
Wetti
ng 
time 
(sec) 
% 
Drug 
content 
 
F1 701 5.68 5.18 0.134 90 60 99.2 
F2 699 6.04 5.07 0.123 80 55 97.4 
F3 700 5.54 5.22 0.093 65 50 99.6 
F4 698 4.32 5.26 0.084 60 52 98.4 
F5 700 4.10 5.17 0.124 40 45 99.3 
F6 699 3.79 5.29 0.171 45 65 99.2 
F7 698 3.05 5.20 0.138 70 59 100.1 
F8 700 3.23 5.27 0.237 60 56 99.6 
F9 698 3.38 5.31 0.264 78 50 99.6 
 
6.3.1. Post-compression evaluation of Sildenafil citrate 
Average weight, Hardness test, Thickness test, Friability, Disintegration time, 
wetting time, Drug content.  
The results of , Average weight,Hardness,Thickness,Friability,Disintegration 
time, wetting time ,Drug content are shown in the table no. 12.The bulk density and 
tapped density for all formulation varied  from 698mg to 701 mg . All the 
formulations passed the weight variation test as results were found to be IP limits of 
±5% weight. The maximum thickness of the formulation was found to be 5.29 ± 0.005 
mm in batch F6 and minimum thickness of the was found to be 5.07 ± 0.001 mm in 
batch F2. The hardness of all the formulation tablets were determined by Pfizer 
hardness tester and it was found to be in the range of 3.05 ± 0.01 to 6.04 kg/cm3. 
Friability of the various batches was found to be in between 0.264 ± 0.14% to 0.084 
%. Wetting time for all formulated tablet were found to be in the range of 40.01 ± 
0.056 to 90.0 ± 0.56 seconds. The wetting time for tablets closely relate to the pore 
size of the internal structure, which affects the penetration of water into the tablets. 
The maximum percentage of the drug content of the formulation was found to be 
100.1 ± 0.33 and maximum percentage of the drug content from all formulation was 
found 98.4 ± 0.46, ensuring the uniformity of the drug content in the all formulations. 
 
 
Figure no 6.15 wetting time for sildenafil citrate F5 
 
Sildenafil citrate tablets after 5 seconds 
  
Figure no 6.16 wetting time for Sildenafil citrate F5 
 
Sildenafil citrate tablets after 15 seconds 
 
Figure 6.17 wetting time for sildenafil citrate F5 
 
 
 
 
 
 
 
 
 
Sildenafil citrate tablets after 25 seconds 
  
  
 
Figure no 6.18 wetting time for sildenafil citrate F5 
 
           Sildenafil citrate tablets after 40 seconds 
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6.4. Dissolution data for chewable tablet 
Table no.13. Dissolution data of chewable tablets 
Time 
in 
min 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
5 15.65 16.32 18.35 14.06 20.48 17.48 12.48 11.79 8.69 
10 18.28 19.62 22.35 26.50 37.49 20.68 29.68 24.69 11.49 
15 25.45 29.40 34.45 38.56 60.67 30.78 45.78 50.48 50.87 
20 40.67 43.67 48.87 44.96 78.48 50.78 60.68 65.67 76.79 
25 60.70 64.68 69.89 74.74 90.79 79.40 88.48 78.45 88.48 
30 70.89 85.78 88.98 90.25 100.5 89.45 98.48 97.65 95.67 
 
Figure no 6.19 Dissolution Profile 
 
 
 
0
10
20
30
40
50
60
70
80
90
100
110
120
0 5 10 15 20 25 30
cu
m
ul
at
iv
e%
dr
ug
 
re
le
as
e 
Time in Minuties 
F1
F2
F3
F4
F5
F6
F7
F8
F9
103 
 
6.5. Dissolution graph for chewable tablet 
All the formulations except batch F5 were not able to release 100 % of drug 
within 30 minutes. F5 formulation released the total drug within 30 minutes which 
will aid in the fast onset of action. This may be attributed to the presence of super 
disintegrants croscarmellose sodium and crospovidone in batch F5. This also might 
have increased by the increased wetting of the tablet resulting in fast dissolution.   
6.5.1 Comparison of optimized formulation (f5) with innovator product (Viagra 
100mg by marketed tablet) 
The optimized formulation (F5) was compared with innovator product, Viagra 
100mg for in-vitro disintegration and dissolution studies. The in-vitro disintegration 
time of F5 formulation was found to be 40 seconds and that of Viagra was found to be 
80 seconds. The in-vitro disintegration time of optimized formulation was found 6 
times lesser than the innovator product. The dissolution time of F5 was found to be 
100.5% in 30 minutes, where as the marketed product showed 98.08 % of drug 
release in 30 minutes. This indicates formulation F5 showed rapid release of the drug 
than the innovator product. 
Table no.14. Comparison of formulation tablet vs marketed tablet 
 
FORMULATION 
CUMULATIVE % DRUG  RELEASE 
0min 5min 10min 15min 20min 25min 30min 
F5 0 20.48 37.49 60.67 78.48 90.79 100.5 
Viagra 0 16.67 30.76 58.78 70.54 86.78 98.08 
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Figure no 6.20. Comparison of marketed tablet vs. sildenafil citrate F5 batch 
 
6.5.2. Stability studies 
 Evaluation of tablet parameters after stability studies at storage condition-
400C/75%RH Period-3Month 
Table no.15. Stability studies 
S.no. Parameter Time duration 
0Month 1Month 2Month 3Month 
1 
Physical 
character 
-- -- -- -- 
2 Friability% 0.42 0.45 0.45 0.42 
3 Hardness[kg/cm3] 6.85 6.81 6.82 6.84 
4 
% drug release of 
at 30min 
100.5 100.25 99.04 98.12 
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6.5.3. Evaluation of pre compression parameters for batches with moringa gum 
by wet granulation method.  
Table no.16.pre-compression parameters for chewable tablet (wet granulation 
method) 
Formulation 
code 
Bulk 
density 
(gm/ml) 
Tapped 
density 
(gm/ml) 
Compressibility 
index (%) 
Hausner’s 
ratio 
Angle 
of 
repose 
F10 0.558 0.685 17.94 1.21 26o.12′ 
F11 0.554 0.680 18.90 1.33 27o.71′ 
F12  0.560 0.726 21.90 1.28 29o.46′ 
 
6.5.4. Angle of repose. 
  All the formulation prepared by wet granulation method showed the angle of 
repose between 26o and 29o  revealing excellent flow property as shown in the  table 
no 16. 
 
6.5.5. Bulk density, tapped density, compressibility index and hausner’s ratio. 
The results of, Bulk density, tapped density, compressibility index and 
hausner’s ratio of batches prepared by wet granulation method are shown in the table 
no. 16. The bulk density and tapped bulk density of the formulation varied from 0.554 
gm/cm3 to 0.560 gm/cm3 respectively. Tapped density for all formulation varied from 
0.680 gm/cm3 to 0.726 gm/cm3. The result of Carr’s consolidation index or (%) 
compressibility index for the entire formulation blend ranged from 17 to 21 shows 
excellent compressibility index and hausner’s ratio for all formulation varied from 
1.21 to 1.33 result in good  flow properties. 
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6.5.6. Post compression parameters 
Table no.17. Post compression evaluation parameters 
Formulatio
n 
Code 
 
Avg. 
Weight 
 
 
Hardness 
(kg/cm2) 
 
 
Thickness 
(mm) Friability  
Disintegration 
time 
(sec) 
Wetting 
time (sec) 
 
%Drug 
content 
 
F10 701 4.85 4.28 0.026 35 55 99.48 
F11 699 4.81 4.41 0.021 25 58 97.56 
F12 700 6.80 4.32 0.022 20 45 95.46 
 
6.5.7. Post-compression evaluation of Sildenafil citrate 
Average weight, Hardness test, Thickness test, Friability, Disintegration time, 
Wetting time, Drug content. 
 The results of, Average weight, Hardness, Thickness, Friability, Disintegration 
time, wetting time ,Drug content are shown in the table no.17. The average weight of 
the tablet varies from 699 mg to 701mg. All the formulation passed the weight 
variation test as results were found to be IP limits of ±5% weight. The maximum 
thickness of the formulation was found to F10 batch 4.28 ± 0.005 mm minimum 
thickness of the batch F11 was found to be 4.41±0.001mm F11.The  hardness of all 
the formulation tablets were determined by Pfizer hardness tester and it was found to 
be in the range to be in the range of 4.80 ± 0.01 to 6.04kg/cm3.The Friability of the all 
formulation tablet were determined by Roche friabiliators found to be in between 
0.021±0.14% to 0.026%. Wetting time for all formulated tablet were found to be in 
the range of 0.50±0.056 to 0.38±0.56 minuties. The wetting time for tablets closely 
releated to the pore size of the internal structure .which is affected the penetration of 
water into the tablets. The maximum percentage of the drug content of the 
formulation was found to be 99.48±0.33 and maximum percentage of the drug content 
from all formulation was found 95.46±0.46, ensuring the uniformity of the drug 
content in the all formulations. 
Figure no.6.21.Wetting time for sildenafil citrate F12 
 
Wetting time for Sildenafil citrate 20seconds 
 
Figure no.6.22.Wetting time for sildenafil citrate F12 
 
Wetting time for sildenafil citrate 30 seconds 
 
Figure no.6.23.Wetting time for sildenafil citrate F12 
 
Wetting time for sildenafil citrate 45 seconds 
6.6. Dissolution data for sildenafil citrate 
Table no.18. Dissolution data of sildenafil citrate  
TIME IN MIN F10 F11 F12 
5 10.54 15.45 20.65 
10 25.54 30.65 38.46 
15 45.01 50.84 69.01 
20 75.65 78.45 82.98 
25 85.78 90.05 95.78 
30 95.09 98.05 100.98 
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. 
Figure no .6.24 Dissolution profile 
 
6.7. Dissolution graph for Wet granulation method for sildenafil citrate 
 The batch F12 released 100 % of the drug within 30 minutes. Hence 
increasing the concentration of moringa gum resulted in the reduction of 
disintegration time and increase of dissolution and wetting time. Hence moringa gum 
can be suitably used with sildenafil citrate as a disintegrating agent for increasing the 
onset of action. 
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Table no.19. Comparison of formulation tablet vs marketed tablet 
 
FORMULATION 
CUMULATIVE % DRUG  RELEASE 
0min 5min 10min 15min 20min 25min 30min 
F12 0 20.65 38.46 69.01 80.98 91.78 100.98 
Sildenafil citrate 0 18.02 35.67 62.03 77.04 80.43 95.08 
 
 
Figure no.6.25. Comparison of marketed tablet vs Sildenafil citrate 
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6.8. Comparison of Optimized formulation (F12) with Innovator Product 
(Sildenafil citrate 100mg by marketed tablet) 
The optimized formulation (F12) was compared with innovator product, 
Viagra 100mg for in-vitro disintegration and dissolution studies. The in-vitro 
disintegration time of F12 formulation was found to be 20 seconds and that of Viagra 
was found to be 80 seconds. The in-vitro disintegration time of optimized formulation 
was found 6 times lesser than the innovator product. The dissolution time of F12 was 
found to be 100.98 in 30 minutes, where as the marketed product showed 95.08 % of 
drug release in 30 minutes. This indicates formulation F12 showed rapid release of the 
drug than the innovator product. 
  
 
 
 
 
 
CHAPTER 7 
SUMMARY AND CONCLUSION 
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7.1. SUMMARY AND CONCLUSION 
• The chewable tablets of taste masked sildenafil citrate were successfully prepared 
by direct compression method and wet granulation method. 
• 12 batches using various additives were prepared and evaluated with an aim of 
presenting sildenafil citrate taste masked by the chewable tablet. 
• Drug excipient compatibility study was performed by FTIR. 
• The unpleasant taste of the sildenafil citrate was masked by intra-granular 
addition of dried calcium carbonate, calcium carbonate from oyster shell and the 
extra-granular addition of sweeteners and flavoring agents. Taste masking study 
was done by using alkalizing agent in different ratio. Sildenafil citrate taste 
masking was increased when dried calcium carbonate quantity was increased 
because of reduction of the solubility of sildenafil citrate. Oyster shell calcium 
carbonate when added to the drug did not masked the taste due to the gritty 
nature of it. 
• F5 batch showed less bitterness, low disintegration time and fast dissolution time 
and hence was taken further comparing with the innovator drug. 
• In the present study disintegrating properties of Moringa Oleifera gum powder 
had been studied in comparison with other commercially available super 
disintegrants. The isolated natural disintegrant exhibits faster drug dissolution 
and disintegration. The isolated gum powder can be effectively used as 
disintegrant for sildenafil citrate with the added advantage of the folkloric 
aphrodisiac activity of it. 
• The physicochemical evaluation results for the powdered blend of all trials pass 
the official limits in the angle of repose, compressibility index, Bulk density, 
Tapped density, Hausner’s ratio. 
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• Hence it may be summarized that the tablets prepared by direct compression 
method might be a perfect and effective formulation to prevent the side effects in 
treating erectile dysfunction”. 
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